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1. INTRODUCTION 
 
1.1. Picornaviruses 
1.1.1. General information 
 
Picornaviruses (family: picornaviridae) are non-enveloped viruses with a single-stranded 
RNA genome of positive sense and an icosahedral capsid. The name picornavirus derives 
from the Greek word pico meaning very small, and RNA referring to their ribonucleic acid 
genome. The name literally means small RNA virus. The family of picornaviridae has been 
object of many studies; the disease caused by one type of picornavirus, foot and mouth 
disease virus (FMDV), was already described in 1514 (Fracastorius, 1546). They are an 
interesting and important target for various studies as picornaviruses are the causative agents 
of several human and animal diseases. 
 
Picornaviridae 
genus species serotypes 
      
Rhinovirus Human rhinovirus (HRV) 102 
  
Bovine rhinovirus (BRV) 3 
  
    
Aphthovirus Foot- and- mouth- disease virus (FMDV) 7 
  
equine rhinitis A virus (ERAV) 1 
  
    
Enterovirus Poliovirus (PV) 3 
  
Coxsackie virus A (CVA) 23 
  
Coxsackie virus B (CVB) 6 
  
Echovirus (EV) 30 
  
Human enterovirus (HEV) 4 
  
Bovine enterovirus (BEV) 2 
  
Porcine enterovirus A (PEV-8) 1 
  
Porcine enterovirus B (PEV-9, PEV-10) 2 
  
Swine vesicular disease virus (SVDV) 1 
  
    
Parechovirus Human parechovirus (HPEV) 2 
  
    
Cardiovirus Encephalomyocarditisvirus (EMCV) 1 
  
TEMV, VHEV 2 
  
    
Hepatovirus Human hepatitis A virus (HAV) 1 
  
Simian hepatitis A virus (SAV) 1 
  
    
Teschovirus Porcine teschovirus (PTV) 10 
  
    
Kobuvirus Aichi virus 1 
  
    
Erbovirus equine rhinitis B virus (ERBV) 1 
Tab. 1 genera of the picornaviridae family 
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According to taxonomy there are 9 genera of classified picornaviruses, which can be seen in 
table 1 (Stanway et al., 2005). More than 200 serotypes among the several genera of 
picornaviruses are known. These can be classified according to their physiological properties 
and their phylogenetic relationships, which is based on alignments of their nucleotide 
sequence. 
 
According to Baltimore’s classification system, picornaviruses are class IV as their genome is 
a single stranded RNA molecule of positive sense with a length of 7,2kb (HRV14) to 8,5kb 
(FMDV). As in all positive sense RNA viruses the genomic RNA is infectious. However, 
intact viral particles are 1x106- fold more infectious. On both ends of the genome, there is an 
untranslated region (UTR). The 5’ UTR is 600 to 1200 base pairs long and contains a higher 
ordered structure, the internal ribosome entry site (IRES), which is responsible for cap 
independent internal initiation of translation. The 3’ UTR is only 50 to 100bp long and plays a 
role in the synthesis of the negative strand. The rest of the genome codes for a single 
polyprotein of 2100 to 2400 amino acids. On the 5’ end there is no cap-structure, but a small 
virally encoded protein, VPg (virus protein, genome linked), which contains approximately 23 
amino acids and is covalently attached to the RNA. The 3’ end is polyadenylated. The 
genome has one open reading frame. The 5’ region of the genome encodes for structural 
proteins, whereas the 3’ region encodes for non-structural proteins (Kitamura et al., 1981; 
Racaniello et al., 1981; Stanway et al., 1983) (Fig.1).  
 
Fig.1: Genome of picornaviruses 
The figure shows the single-stranded positive sense RNA genome of picornaviruses. On both 
ends there is an UTR, the rest of the genome codes for a single polyprotein. On the 5’ end 
VPg, a small virally encoded protein, is attached, the 3’ end is polyadenylated. The black 
shading marks 2Apro and 3Cpro the two proteases that cleave the polyprotein into segments. 
 
The genome has a length of 2500nm, whereas the viral particles have a diameter of only 27 to 
30nm. This means that the genome has to be packed very tightly into the icosahedral capsid. 
The capsid of the viral particle consists of a tightly packed arrangement of 60 protomers. Each 
protomer consists of four different polypeptides (VP1, VP2, VP3, and VP4). VP2 and VP4 
derive from the cleavage of the primary protomer VP0 (Arnold & Rossmann, 1990). In each 
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of the 12 axes of symmetry a pentamer consisting of 5 protomers is arranged. This results in 
the icosahedral capsid in which the viral RNA genome is packed (Fig.2). 
 
 
Fig.2: Assembly of the viral particle 
 A shows the assembly of the viral particle from the nascent polyprotein to the mature virion. 
Graph B demonstrates the packaging of the viral proteins VP1, VP2 and VP3 in a picornaviral 
capsid. The x-ray structure of the picornavirus HRV14 is given in C. VP1 is marked in blue, 
VP2 in green and VP3 is marked in red. VP4 is only visible on the inside of the particle. A 
has been taken from [1], picture B and C from [2]. 
 
Viruses have to keep their genomes small and have evolved different strategies to do so. 
Picornaviruses have two major strategies to increase the capacity of their small genome. First, 
they are translated using internal initiation of translation as their 5’ UTR contains an IRES 
(Pelletier et al., 1988; Jang et al., 1988). Secondly, their positive sense RNA genome contains 
a single ORF that is translated into a single polyprotein. This saves space as only one mRNA 
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is required for several proteins. Following translation the polyprotein is processed into the 
viral proteins by the viral proteases 2A, 3C and L. More details on picornaviral proteases are 
given in chapter 1.3.  
 
 
The replication of picornaviruses takes entirely place in the cytoplasm. The first step in viral 
replication is the attachment of the virion to the membrane of the host cell. For attachment the 
various serotypes use different receptors. It is believed that in most picornaviruses the virus 
enters the cell by receptor-mediated endocytosis. However, some picornaviruses, e.g. 
poliovirus enter via structural rearrangements (Zeichardt, 1985; Jackson et al., 1996; Curry et 
al., 1995; Willingman et al., 1989). In case of receptor-mediated endocytosis, the viral 
particle is drawn into the cytoplasm when the virus- receptor complex is invaginated into the 
cell and then closed off into a clarithin coated vesicle. These clarithin coated vesicles fuse 
with intracellular vesicles forming endosomes. Inside the vesicles, a significantly lowered pH 
(pH < 5) can be found. The uncoating of the virus is pH dependent as the low pH results in a 
conformational change of the capsid (Madshus et al., 1984). Due to this conformational 
change, the VP4 is lost and the surface becomes more lipophilic. The viral RNA, to which the 
VPg is covalently attached, is released into the cytosol through pores (Giranda et al., 1992). 
Subsequently, the translation of the polyprotein starts. The positive sense viral RNA is used as 
a mRNA and translated into a polyprotein of about 220kDa. After the cis processing in which 
the viral proteases cleave the polyprotein into segments, RNA polymerase is released. This 
polymerase uses the positive sense strand as a template to create the complementary negative 
strand. To produce the negative strand, the VPg is esterified with uridine. The VPg-pUpU 
complex interacts with the poly-A tail and can be used as a primer for the polymerase. The 
negative strand then forms a replicative intermediate in the endoplasmic reticulum. This 
multistranded replicative intermediate can be used to replicate several positive sense RNAs 
concomitantly. (Richards et al., 1984; Pata et al., 1995) These positive sense RNAs are again 
used for the translation of the viral proteins and the replication of the negative sense strands. 
The newly synthesised capsid proteins arrange first to protomers and then to pentamers. Then, 
the positive sense RNA condenses to a compact core around which 12 pentamers are arranged 
to form the viral capsid. The mature virion is created after the processing of VP0 into VP2 
and VP4. Following this, the readily packed viral particles accumulate in the cell and are 
released. The release of the virus from the cell is not fully understood. As most non-
enveloped viruses are dependent on disintegration of the host cell, the mature virus is 
probably accumulated until the cell is lysed. However, some form of cellular exocytosis 
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(Sandoval & Carrasco, 1997) or induced apoptosis (Rasilainen et al., 2004) may play a role as 
well. The steps of the replication cycle are summarized in Fig.3. 
 
 
Fig.3: The viral replication cycle of a picornavirus 
The figure demonstrates the viral life cycle of a picornavirus starting with binding to the 
receptor, followed by the entry of the cell and uncoating of the virus. The virus then uses the 
cellular machinery to translate its polyprotein. The cleavage of the two isoforms of eIF4G by 
2Apro then leads to a shut-off of host cell translation while the viral proteins are still translated 
through a cap independent mechanism. The viral life cycle is then completed by packaging 
and release of the viral particle. Fig. 3 has been taken from Whitton et al., 2005) 
 
1.1.2. Rhinoviruses 
 
Being the main causative agent of common cold, the 102 serotypes of human rhinovirus 
(HRV) are the most common infective agents in humans (Monto et al., 1987; Rueckert et al., 
1996). The name is derived from the Greek word rhino meaning nose.  
 
Rhinoviruses are transmitted either directly from person- to- person via airborne infection by 
aerosols of respiratory droplets, or indirectly via respiratory droplets deposited on hands 
which are transported by the fingers to the nose or the eyes (Hendley & Gwaltney, 1988). 
Rhinoviruses occur worldwide and cause infections of the upper respiratory tract, where they 
affect the epithelial layer of the nose. Their ideal growth temperature is 33°C, which 
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corresponds to the temperature inside the nose. Therefore, rhinoviruses rarely cause infections 
of the lower respiratory tract, as they grow poorly at 37°C. The incubation period for 
rhinovirus infections is only 8- 10 hours. The infection is normally harmless. Complications 
are mainly due to secondary bacterial infections which may cause problems in children and 
old people (Miller et al., 2007). However, rhinovirus infections are an economic factor as they 
cause days absent from work (Bramley et al., 2002; Fendrick et al., 2003). Protection from 
infection is maintained by antibodies in the respiratory tract (Couch, 1996). However, it has to 
be remarked that these antibodies do not circulate lifelong, but are short-living. A vaccine 
against rhinoviruses does not exist as there is little- to no cross- protection between the 
serotypes. 
 
The various serotypes of HRVs can be separated into different groups of the rhinovirus genus. 
The first classification is based on an alignment of the nucleotide sequences of the VP4/VP2 
region (420nt). HRV- A consists of 74 serotypes, while 25 serotypes can be classified as 
HRV- B.(Savolainen et al., 2002b) HRV- 87 could be identified as human enterovirus 87 by 
VP4- based molecular diagnosis (Savolainen et al., 2002a; Ishiko et al., 2002). HRV 1 is 
separated into two subtypes, HRV-1A and HRV-1B. A second classification scheme is based 
on the receptors used by the different serotypes. HRVs that use the LDL- receptor are 
members of the so-called minor group, whereas HRVs using ICAM- receptors belong to the 
major group. (Schober et al., 1998) 
 
In this thesis, the proteins of two serotypes of HRV, HRV2 and HRV14, were examined. 
According to the classification systems described above, HRV2 is a member of the HRV- A 
group and a minor group virus. HRV14 on the other hand belongs to HRV- B and the major 
group. Thus the two serotypes differ in their sequence and the type of receptor they use 
(Duechler et al., 1993). 
 
1.1.3. Polioviruses 
 
Poliovirus (PV) belongs to the genus enterovirus and is the causative agent of poliomyelitis. It 
was first isolated in 1908 by Landsteiner and Popper (Landsteiner & Popper, 1909), but first 
cases of poliomyelitis were already documented in prehistoric Egyptian drawings. It is one of 
the most well-characterized viruses and often used as a model system for RNA viruses. 
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There are three serotypes of poliovirus, PV1, PV2 and PV3. The length of the genome of each 
is about 7500 bp. The capsid proteins differ between the three serotypes. PV1 is the most 
common serotype in nature. There is evidence that PV emerged from C- cluster coxsackie A 
viruses through a mutation in the capsid. This mutation probably resulted in a change of the 
used receptor and a change of the pathogenicity of the virus. (Ping et al., 2007) 
All serotypes of PV use CD155 as receptor, which can be found in the cells of humans, higher 
primates and old world monkeys. Poliovirus naturally infects only humans. PV is an 
enterovirus and is transferred via the faecal- oral route, which means that the virus is found in 
the faeces and can replicate in the alimentary tract when ingested. This is only possible as PV 
is acid-stable and not destroyed in the acidic surroundings of the alimentary tract. 
 
The incubation period of PV lasts for 7-14 days. The virus is replicated in the intestinal tract 
and then attacks the local lymph nodes and enters the bloodstream (viremia). In more than 
90% of the cases the viremia is only transient and the poliovirus infection is asymptomatic. In 
about 5% of the cases the virus spreads and replicates in other tissues such as brown fat, 
muscle and the central nervous system (CNS). This sustained infection results in an aseptic 
meningitis which is accompanied by minor symptoms such as fever, headache and a sore 
throat, however there are no signs of paralysis. In only 1% of the infections the virus enters 
the CNS and replicates in motor neurons within the spinal cord, the brain stem and the motor 
cortex. This results in destruction of the motor neurons, which leads to temporary or 
permanent paralysis. In rare cases, respiratory paralysis and death occur. 
 
Individuals that were exposed to PV develop lifelong immunity. The antibodies are present in 
the tonsils and the gastrointestinal tract. It has to be noted that there is no cross immunity 
between the three serotypes. 
 
Immunity against all three serotypes can be obtained by vaccination. The Sabin poliovirus 
vaccine is a live viral vaccine, consisting of one strain of live attenuated PV for each of the 
three serotypes. The vaccine strains are produced by passage of the virus through monkeys or 
monkey cells (Sabin, 1965). The attenuation results in a loss of the neuroviolence of the virus 
in humans while the virus is still able to replicate in the intestine and generate immunity. B- 
and T- cell response is produced as well as memory B- cells. Vaccine associated disease only 
occurs rarely (1 in a million doses). 
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Poliovirus infection was widespread in the 1950’s. Large vaccination campaigns helped to 
eradicate the number of annual diagnosed cases by 99%. However, PV has not been totally 
eradicated and is still endemic in parts of Nigeria, India, Pakistan and Afghanistan. 
1.1.4. Coxsackieviruses: 
 
Coxsackieviruses (CV) belong to the genus of enteroviruses, which means that they replicate 
in the intestines. They are separated into the Coxsackie A viruses (CVA), consisting of 23 
serotypes and Coxsackie B viruses (CVB), consisting of 6 serotypes (Tab.2). 
 
Enterovirus 
Subtype Species Serotypes 
Human enterovirus A Coxsackievirus A2- 8, A10, A12, A14, A16 21 
  
Human enterovirus 71, 76, 89- 92   
 
Simian enterovirus 19, 43, 46, A13  
Human enterovirus B Coxsackievirus B1- 6, A9 57 
  
Echo- virus 1- 9, 11- 21, 24- 27, 29- 33   
  
Human enterovirus 69,73-75,77-88,93,97,98,100,101   
 
Simian enterovirus SA5  
Human enterovirus C Coxsackievirus A1, A11, A13, A17, A19- 22, A24 17 
 
Poliovirus 1- 3  
 
Human enterovirus 95, 96, 99, 102, 104  
Human enterovirus D Human enterovirus 68, 70, 94 3 
Tab.2. Classification of human enteroviruses  
The data for this table was taken from [3]. 
 
The virus is transmitted via the faecal- oral route from person- to- person for example by 
unwashed hands or contaminated water. The viruses use receptors that are primarily found in 
the lymphatic tissue of the throat, where the virus replicates. For CVA various integrin 
receptors are used, vibronectin for example is the receptor for serotype A9 (Roivainen et al., 
1994) (Roivainen et al., 1996), while ICAM-1 is used by A13, A18 and A21 (Colonno, 1986). 
All six serotypes of CVB use the CAR receptor (coxsackievirus and adenovirus receptor) 
(Bergelson et al., 1997). Additionally DAF (Decay accelerating factor) can be used as a 
receptor by serotype B1, B3 and B5 (Bergelson et al., 1995). 
 
As coxsackieviruses are acid-stable, they can enter the gastrointestinal tract and infect the 
epithelial layer of the intestine. The incubation period can be between 2 and 35 days, however 
1 to 2 weeks are characteristical for most infections. The majority of the infections are 
asymptomatic or cause only mild symptoms. Neutralizing antibodies are produced. However, 
in some cases the virus is able to enter the bloodstream and spread to different organs, 
according to the type of the enterovirus. Severe diseases that are related with coxsackieviruses 
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include meningitis, encephalitis and myocarditis. A list of the diseases and the serotype of CV 
that they are related to is given in Tab.3 (King & Mills, 2000; Rieder et al., 2001). CVA is 
normally related with exanthema, herpangina and hand, foot and mouth disease, whereas 
CVB is related with internal diseases (Kayser et al., 1998). Coxsackie B4 has been identified 
as a possible cause of Diabetes mellitus type 1 as CVB4 is able to trigger an autoimmune 
reaction that results in destruction of the insulin producing beta cells of the pancreas 
(Roivainen et al., 2000). 
 
  Serotype disease 
Coxsackievirus A A2- 6, A8, A10 herpangina 
  
A10 acute lymphatic pharyngitis 
  
A2, A4, A7, A9, A10, A23 aseptic meningitis 
  
A7, A9 paralysis 
  
A2, A4, A6, A16, A23 macular exanthema 
  
A4- 6, A9, A10, A16 vesicular exanthema 
  
A5, A10, A16 Hand, foot and mouth disease 
  
A9, A16 pneumonia 
  
A21, A24 common cold 
  
A4, A9 hepatitis 
  
A18, A20- 22, A24 diarrhoea 
  
A24 acute haemorrhagic conjunctivitis 
Coxsackievirus B B1- 5 pleurodynia 
  B1- 6 aseptic meningitis 
  B2- 5 paralysis 
  B1- 5 meningoencephalitis 
  B1- 5 Bornholm disease 
  B1- 5 pericarditis, myocarditis 
  B4, B5 Infections of the upper respiratory tract 
  B1, B3, B5 macular exanthema 
  B5 hepatitis 
  B1- 6 fever 
  B1, B2, B4 pancreatitis 
  B4 Diabetes mellitus Type 1 
Tab.3. Diseases related to coxsackieviral infection  
The figure was modified according to Roetzer, 2004. 
 
Coxsackie B viruses frequently cause an inflammation of the myocytes of the heart, termed 
myocarditis. Myocarditis is connected with congestive cardiomyopathy (CCM), a severe 
disorder of the heart muscle (Liu et al.,1993). In 30% of the patients suffering from CCM, an 
enteroviral infection of the heart muscle could be detected (Baboonian et al., 1997). CCM 
may be either acquired or caused by genetic predisposition and causes mainly an enlargement 
of the ventricles of the heart which results in cardiac insufficiency. 
It has been shown that mutations in proteins of the cytoskeleton, especially dystrophin, play 
an important role in hereditary CCM (Koenig & Kunkel, 1990) (Nigro et al., 1994) (Malhotra 
et al., 1988). Dystrophin is a cytoplasmic protein and part of the protein complex that 
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connects the intracellular cytoskeleton of muscle fibres with the surrounding extracellular 
matrix (Straub et al., 1997) (Chien, 1999).  
In CCM that is caused by viral infection, CV 2Apro cleaves the Hinge-3 region of dystrophin, 
which results in a malfunction of the cytoskeleton (Badorff et al., 1999; Badorff et al., 2000). 
The same malfunction is found in hereditary CCM, in which the expression of cytoskeleton 
proteins is affected. The damage of the cytoskeleton by processing of dystrophin is probably 
used to facilitate the release of viral particles from infected cells (Xiong et al., 2002). 
 
1.2. Translation in eukaryotic cells and during viral infection 
 
Viruses can replicate themselves only when they are infecting a host cell. They are not able to 
replicate on their own, as their own genome does not code for the machinery for protein 
synthesis. They are dependent on the host cell for translation. Using the host cell machinery 
for translation helps the virus to keep its own genome small. Most viruses therefore have 
found mechanisms to alter the machinery for translation in the host cell in a way that 
translation of the viral RNA is favoured. In picornaviruses, this results in a complete shut-off 
of host cell translation, so only viral RNA is translated. 
 
It is necessary to examine the events of translation in eukaryotes first, to understand how 
picornaviruses achieve the host cell shut- off. Translation is the process in which proteins are 
produced from an mRNA template, which is read 5’ to 3’, according to the amino acid 
sequence which is coded by the mRNA. Usually each mRNA codes for a single protein. As 
the 4 different nucleotides of the mRNA have to code for the 20 different amino acids that 
build proteins, a one by one transfer of information is not possible. Therefore, each amino 
acid of the polypeptide produced is coded by a triplet of bases, the so-called codon.  
 As these codons are unable to recognise and bind an amino acid directly, an adapter is needed 
to achieve binding to the amino acid coded for. This adapter is the transfer RNA (tRNA), 
which ensures that the amino acids are transported to the right codon. It has a 3’ terminal site 
for amino acid attachment and contains base triplets complementary to the codons on the 
mRNA, the so called anticodons. As there are 61 different base triplets, but only 20 amino 
acids they code for, the genetic code is degenerate in that several amino acids are encoded by 
more than one codon. Thus, some tRNAs have to recognize more than one codon. The 
proposed mechanism for that is the wobble hypothesis, which states that exact base pairing is 
only necessary for the first two bases, while a mismatch at the last position can be tolerated 
(Crick, 1966). The adjustment of the tRNA and the codons takes place in the 40S subunit of 
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the ribosomes, which is the small subunit of the 80S ribosomes of eukaryotes. In the large 60S 
subunit of the ribosomes the formation of the peptide bond is catalysed, so the polypeptide 
chain can be elongated. 
As long as no protein is synthesized, the two subunits of the ribosome are separated. To start 
protein synthesis, the 40S subunit scans the mRNA in 5’ to 3’ direction for an AUG codon 
and binds to it (Kozak et al., 1978). Then the 60S subunit is recruited and the 80S ribosome 
complex is composed using a single GTP (Merrick et al., 1979). The mRNA then is drawn 
through the ribosome. As soon as the codons pass the active site of the ribosome, the 
nucleotide sequence of the mRNA is translated into an amino acid sequence, using the tRNA 
as an adapter. When a stop codon is reached, the two subunits of the ribosome separate and 
the newly synthesized protein is released. 
 
Of the three parts of translation, - initiation, elongation and termination- initiation is the 
crucial part as most regulatory measures affect this part. Several proteins, the so called eIF’s 
(eukaryotic initiation factor) are involved in this process (Schreier et al., 1977; Trachsel et 
al.,1977). Additionally ATP and GTP are hydrolysed. The eukaryotic initiation factors and 
their function are described in Tab.4. 
 
Initiation 
factor Activity 
eIF- 1 facilitates mRNA binding by repositioning of met- tRNA 
eIF- 2 formation of the ternary complex 
eIF- 2A AUG- dependent binding of the met- tRNA to the 40S ribosome 
eIF- 2B GTP/GDP exchange during eIF- 2 recycling 
eIF- 3 antiassociation of the ribosome subunits, binding to the 40S subunit 
PABP binds to the polyA of the mRNA, provides a link of the poly A tail to eIF- 4G and by this promotes circularization of the mRNA 
Mnk1/Mnk2 kinases that phosphorylate eIF- 4E to increase association with the cap- structure 
eIF- 4A ATPase- dependent RNA helicase 
eIF- 4E recognition of the 5' cap, binds to 4G 
4E- BP  binds to eIF- 4E in its dephosphorylated form and represses its function, releases eIF- 4E 
when phosphorylated, which results in increased initiation of translation 
eIF- 4G scaffolding protein, works as adapter and therefore plays a key role in the formation of the 
mRNA- ribosome translation initiation complex   
eIF- 4F  
initiation factor complex, composed of eIF- 4A, eIF- 4E, eIF- 4G, PABP and Mnk1 (Mnk2); 
responsible for the binding of the mRNA to the 40S subunit, the ATPase RNA helicase 
activity and the interaction between cap structure and polyA tail 
Tab.4. Eukaryotic initiation factors and their function 
The function of eIF4A, eIF4E, eIF4G and eIF4F is reviewed in (Gingras et al., 1999). 
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At the start of initiation of translation, a complex composed of the mRNA, the ribosome and 
the initiator met- tRNA is formed. Initiation of translation can now be performed by two 
different mechanisms: either cap- dependent or cap- independent via an IRES. In cap- 
dependent translation initiation, the eIF4E component of the cap binding complex interacts 
with the 5’ cap structure of the eukaryotic mRNA (Shatkin, 1976) and searches for the first 
start codon, AUG. In cap- independent translation initiation the translation initiation complex 
is bound to the IRES (internal ribosome entry site), a higher ordered RNA structure. The first 
mechanism is used in eukaryotic cells, whereas picornaviruses use cap- independent initiation 
as they have an IRES but no cap- structure (Nomoto et al., 1976; Pelletier et al., 1988; Jang et 
al., 1988). Both ways of translation initiation will now be examined in more detail and are 
summarized in Fig.4. 
 
In cap- dependent initiation of translation binding to the translation initiation factor complex 
eIF4F plays an important role. eIF4F is composed of the 3 primary subunits eIF4E, which 
recognises the 5’ cap of the mRNA, eIF4A, a RNA helicase and eIF4G, the adaptor protein 
plus at least 2 additional factors, PABP and Mnk1. First, cellular mRNA is recognised by the 
complex and then bound by eIF3. This recruits the 40S ribosomal subunit in a complex with 
eIF2- Met- tRNA- GTP, eIF3 and eIF4A to the mRNA. Then the cellular mRNA is unwound 
by eIF4A close to the AUG, where the ribosome can bind. After eIF4E binds to the cap, the 
N-Terminus of eIF4G binds eIF4E, while the C-Terminus binds to eIF4A. The 40S subunit of 
the ribosome binds to eIF4G indirectly via eIF3. eIF4G has a crucial function in translation as 
it connects the initiation factor complex and the 40S subunit of the ribosome. 
 
The 40S subunit then scans the 5’ noncoding region of the mRNA until the authentic start 
codon is reached. At the AUG the 60S subunit of the ribosome joins the complex and the 
initiation factor complex is released. Following this, elongation starts and the appropriate 
amino acids are guided to the exit-site of the ribosome. The polypeptide chain is elongated 
until a stop- codon is reached. There the release protein eRf1 exerts hydrolysis between the 
polypeptide chain and the tRNA. Finally the ribosome releases the protein and the translation 
complex falls apart. 
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Fig. 4: Cap dependent and cap independent initiation of translation 
In picture A the formation of the translation initiation complex during cap dependent 
translation is shown. Here eIF4E binds to the 5’ cap of cellular mRNA and is bound to the N-
terminus of eIF4G. The C-terminus of eIF4G binds the 40S ribosomal subunit via eIF3 and 
eIF4A directly thereby connecting the cap with the 40S. The arrows indicate where Lpro and 
2Apro cleave eIF4G. This cleavage results in the separation of the cap bound to eIF4E from 
the rest of the initiation complex, which disables protein synthesis from cellular mRNA and 
results in the shut-off of host cell translation. Picture B shows the situation after the cleavage 
for cap independent translation. The C-terminal domain of eIF4G is still able to form a 
complex with picornaviral RNA, as their 5’ noncoding structure contains an IRES, which can 
be used instead of a cap structure. Figure 4 was taken from (Seipelt et al., 1999)  
 
Picornaviruses are not able to use the cap-dependent mechanism for initiation of translation as 
their RNA genome does not contain a 7- methyl G cap structure as it is found at the 5’ end of 
cellular mRNA. Instead of the cap structure a small viral protein, VPg, is linked to their 5’ 
end (Lee et al., 1977; Flanegan et al., 1977). Additionally picornaviruses have a long, highly 
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structured 5’ noncoding region and several non- authentic start codons that could preclude 
ribosomal scanning (Kitamura et al., 1981; Racaniello et al., 1981). Therefore, initiation of 
translation in picornaviruses is performed by a cap-independent mechanism known as internal 
ribosome entry (Pelletier et al., 1988; Jang et al., 1988). In cap- independent translation the 
40S ribosomal subunit binds to an internal ribosome entry site (IRES) instead of the cap and 
initiation starts at the authentic start codon.  
Internal ribosome entry sites have been identified for all picornaviruses and are located in the 
5’ noncoding region, a part of the genome which sequence and RNA secondary structure are 
highly conserved among the viral serotypes of each genera. The picornaviral IRESs are 
mainly divided into two groups according to their structure homology and sequence similarity 
(Wimmer et al, 1993). Group 1 includes the IRESs of enteroviruses and human rhinoviruses, 
group 2 that of cardio- and aphthoviruses. In entero- and rhinoviruses the 5’ noncoding region 
contains six major stem-loops upstream of the start site of translation, the IRES being located 
between stem-loop II and V (Pelletier et al., 1988). Group 2 IRESs as well contain highly 
conserved stem-loop structures, the largest loop being stem-loop I. 
 
The use of an IRES that enables cap-independent initiation of translation is highly favourable 
for picornaviruses as it allows them to interfere with host cell translation. Picornaviruses 
evolved a mechanism that is used to inhibit protein synthesis of the host cell that uses cap-
dependent initiation of translation. This finally results in the host cell shut-off (Kräusslich et 
al., 1987; Lloyd et al., 1987; Jewell et al., 1990). This is achieved by the cleavage of the two 
isoforms of eIF4G. eIF4G binds eIF3 that is associated with the ribosome and delivers the 
40S subunit to the mRNA in doing so (Lamphear et al., 1995; Mader et al., 1995). It consists 
of two isoforms: eIF4GI and eIF4GII (Yan  et al., 1992; Gradi et al., 1998) which are 41% 
identical and functionally complement each other (Gradi et al., 1998; Imataka et al., 1998). 
 
As remarked above, eIF4G has a crucial function in translation as it connects the initiation 
factor complex and the 40S subunit of the ribosome. Its N-terminus binds directly to eIF4E, 
which interacts with the cap structure of the mRNA, while its C-terminus binds to eIF4A and 
the small ribosomal subunit via eIF3. After the cleavage of the two isoforms of eIF4G by the 
picornaviral proteases, it can not bind to eIF4E anymore, while the 40S subunit and eIF4A 
can still be bound on the C- terminus. This separation of the cap structure bound to eIF4E 
from the 40S subunit means that initiation of translation via an IRES is still possible, whereas 
cap- dependent translation is cut off. In cap- independent initiation of translation, only the C-
terminal end of eIF4G is used, as the internal IRES can be used for initiation of translation. 
As cellular mRNAs are translated in a cap- dependent manner, translation in the host cell 
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stops, whilst the viral mRNA can still be translated. It has been shown in PV1 and HRV14 
that host cell shut off coincides with the cleavage of eIF4GII while the cleavage of eIF4GI 
occurs earlier (Gradi et al., 1998; Svitkin et al., 1999), whereas in HRV2 both isoforms are 
cleaved at similar rates (Seipelt et al., 2000). 
 
The cleavage of the two isoforms of eIF4G is performed by the picornaviral proteases 2Apro 
or Lpro. In enteroviruses and human rhinoviruses the cleavage is exerted by 2Apro, in FMDV 
by Lpro. A deletion of the proteinase responsible for the cleavage of eIF4G results in an 
attenuated phenotype (Kanno et al., 2001; Sakoda et al., 2001; Brown et al., 1996). The 
cleavage site on eIF4GI of HRV2, PV1 and CVB4 2Apro has been identified as 
LeuSerThrArg681*GlyProProArg (Lamphear et al., 1993; Zamora et al., 2002), that of 
eIF4GII lies seven amino acids C-terminal of it being ProLeuLeuAsnVal699*GlySerArgArg 
(Gradi et al., 2003). The cleavage site for HRV14 2Apro has not yet been determined. Lpro 
cleaves eIF4GI seven residues apart from rhinovirus 2Apro at 
AlaAsnLeuGly676*ArgThrThrLeu (Kirchweger et al., 1994) and eIF4GII immediately 
adjacent to the site cleaved by HRV 2Apro at LeuAsnValGly700*SerArgArgSer (Gradi et al., 
2004). Further information on the activity of these two proteases will be given in the 
following chapter. 
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1.3.  Picornaviral proteases 
 
1.3.1. General information 
 
Proteases are enzymes that are able to cleave proteins or peptides by hydrolysis of peptide 
bonds. They can be qualified either by the type of proteolytic reaction they catalyse or by 
their active site. Proteases which cut at the N-Terminus are classified as amino peptidases, the 
ones that cut at the C-Terminus are regarded as carboxy peptidases. According to the reactive 
groups in their active site, they can be divided into six groups: serine proteases (e.g. 
chymotrypsin), threonine proteases (e.g. the proteasome), cysteine proteases (e.g. papain), 
aspartic acid proteases (e.g. pepsin), glutamic acid proteases (e.g. the germination protease) 
and metalloproteases (e.g. pepsin) (Barrett et al., 1998). 
 
Hydrolysis of the peptide bond is achieved by different mechanisms. One way is to create a 
nucleophilic cysteine or threonine residue or make a water molecule nucleophilic, so it can 
attack the carbonyl group of the peptide bond. A frequently used strategy to create a 
nucleophile is using a catalytic triad, a set of three functional groups in the active site of 
proteases. These functional groups typically are a nucleophilic which attacks the carbonyl 
group of the peptide bond; an acid- base catalyst which protonates the leaving group and the 
oxyanion hole; and an electrophilc structure that stabilizes the negatively charged carbonyl 
group (Ryan & Flint, 1997; Chernaia et al., 1993). Usually a histidine is used to activate 
serine, cysteine or threonine as a nucleophile. 
 
Proteases play a major role in picornaviruses as their genome was shown to encode 
proteolytic enzymes that are responsible for the processing of the viral polyprotein into the 
mature viral proteins (Lawrence & Thatch, 1975; Pelham, 1987; Gorbalenya et al., 1979; 
Palmenberg et al., 1979; Svitkin et al., 1979). The first proteinase that was found was 3Cpro, 
which is responsible for the majority of cleavage events on the polyprotein. Following this, 
the 2Apro of entero- and rhinoviruses (Toyoda et al., 1986) and the Lpro of FMDV (Strebel & 
Beck, 1986) were identified. 
 
Alignments of the amino acid sequences of picornaviral proteases with well-established 
models of these protease classes can be used to predict their structure. For the picornaviral 2A 
and 3C proteases this revealed that they are serine proteases with a chymotrypsin- like fold 
and a cysteine in their active site, whereas Leader protease is a cysteine protease with a 
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papain- like fold (Guarné et al., 1998; Petersen et al., 1999). The sequences of picornaviral 
proteases have been reviewed (Ryan & Flint, 1997). 
 
The RNA genome of picornaviruses is translated into a single polyprotein, which is 
subsequently cleaved into the various viral proteins by the picornaviral proteases. The first 
cleavage is used to separate the structural proteins at the N-Terminus from the non-structural 
proteins at the C-Terminus (Toyoda et al., 1986). This separates P1, the precursor of the 
capsid proteins VP1 to VP4, from P2 and P3, the precursor of the non-structural proteins 2A 
to 2C and 3A to 3D. Following this, P1 is cleaved into VP1, VP3 and VP0. VP0 is the 
precursor protein of VP2 and VP4. P2 and P3 are separated and then cleaved into the 
according proteins.  
 
The first cleavage performed by the picornaviral proteases is a cis cleavage used to free 
themselves from the polyprotein (Toyoda et al., 1986). As the proteases perform the cis 
cleavage cotranslationally, the full length polyprotein is never found in living cells. As soon 
as the proteases have cleaved themselves from the polyprotein, they start to cleave in trans. 
This strategy is used to control the genetic expression of the polyprotein. Proteins with 
different activities can be generated using different cleavage sites. 
 
The first cleavage is achieved by 2Apro in rhino-, entero-, erbo-, cardio-, tescho- and 
aphthoviruses. In hepato- parecho- and kobuviruses, 2A is not proteolytically active and the 
cleavage between structural and non- structural proteins is performed by 3Cpro (Jia et al., 
1991; Martin et al., 1995; Schultheiss et al., 1995). In cardio- and aphtoviruses, the leader 
protein precedes P1. In aphthoviruses the leader protein  is a papain-like cysteine protease 
(Gorbalenya et al., 1991; Guarné et al., 19989) which cleaves between its own C-Terminus 
and the N-Terminus of VP4. In cardioviruses the leader protein is not proteolytically active, it 
abrogates the anti- viral response of the host by interfering with nucleo-cytoplasmic transport 
(Delhaye et al., 2004; Lidsky et al., 2006; Porter et al., 2006). The cleavage between the C-
terminus of the leader protein and the N-terminus of VP4 is achieved by 3Cpro. The leader 
protein in cardioviruses abrogates host anti-viral response by interfering with nucleo-
cytoplasmic transport. All further cleavages except the cleavage of VP0 to VP2 and VP4 are 
performed by 3Cpro or its precursor 3CDpro, which are proteolytically active in all 
picornaviruses. The cleavage of VP0 to VP2 and VP4 takes place during maturation of the 
viral particles after VP0 has been assembled into the procapsid and is catalysed by a yet 
unknown proteolytical activity (Arnold et al., 1987; Harber et al., 1991; Basavappa et al., 
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1994). A scheme of the processing of the polyprotein is given in Fig.5, Fig.6 summarises the 
proteolytic processing in the picornavirus genera. 
 
 
Fig.5: Polyprotein processing 
A summary of the steps for polyprotein processing in rhino- and enteroviruses is given in this 
figure. The first cleavage is performed by the 2Apro which separates structural from non-
structural proteins. All further cleavages are performed by 3Cpro or its precursor 3CD. The 
figure above was modified according to [4]. 
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Fig.6: Processing in the different genera  
The figure shows the processing of the polyprotein in the different picornaviral genera and the 
involved proteases. The figure was taken from [5]. 
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1.3.2.  Leader protease (Lpro) 
 
The leader protein is present in cardioviruses and aphthoviruses, however, it is only 
proteolytically active in aphthoviruses. The Lpro of aphthoviruses such as FMDV is a cysteine 
protease with a papain- like fold. Lpro is the first protein encoded on the FMDV polyprotein 
and first cuts between its own C-Terminus and the N-Terminus of VP4 to free itself from the 
polyprotein (Strebel & Beck, 1986). Additionally, it cleaves the two isoforms of eIF4G 
inhibiting the cap- dependent translation of the host cell. This cleavage results in a shut-off of 
host cell translation (Devaney et al., 1988). 2Apro performs a similar cleavage in rhino- and 
enteroviruses, but has been shown to cleave at a different sequence (Kirchweger et al., 1994). 
The catalytical triad of Lpro consists of cysteine, histidine and aspartic acid (Roberts & 
Belsham, 1995; Skern et al., 1998). The crystal structure of foot- and- mouth- disease Lpro has 
been published (Guarnè et al., 1998). It reveals a globular catalytic domain very similar to 
that of the papain superfamily and a flexible C-terminal extension. This extension supports 
intramolecular self-processing and the binding of eIF4GI (Foeger et al., 2002). 
 
1.3.3.  3C protease (3Cpro) 
 
The 3C protease and its precursor 3CDpro are responsible for the majority of cleavage 
reactions during polyprotein processing and are found in all genera of picornaviruses 
(Dougherty & Semler, 1993). According to inhibitor studies, it was predicted to be a cysteine 
protease, however three dimensional modelling and sequence alignments implied a 
chymotrypsin-like fold that is normally typical for serine proteases. These predictions were 
verified by the crystal structures of the 3Cpro of hepatitis A virus (Allaire et al., 1994), HRV14 
(Matthews et al., 1994), PV1 (Mosimann et al, 1997) and FMDV (Birtley et al., 2005). It has 
to be remarked that the 3Cpro has - helices on the C- and the N-termini, whereas 
chymotrypsin has an - helix only at the C-Terminus. These helices play a role in RNA 
binding, which takes place at the 5’ noncoding region of the picornaviral genome. The 5’ 
terminal 100 nucleotides of entero-, rhino-, and hepatoviruses form a cloverleaf structure that 
is required for viral replication. However, the cloverleaf structure has no binding site for the 
RNA-dependent RNA polymerase (3Dpol). Instead this structure binds to 3Cpro or its precursor 
3CDpol (Andino et al., 1990), binding to the precursor was reported to be 10-fold stronger 
(Andino et al., 1993). The RNA binding site of 3Cpro comprises one face each of the N- and 
C-terminal helices as well as the part of the polypeptide chain that links the two domains. It 
was shown that the amino acid sequence Lys Phe Arg Asp Ile is involved in RNA binding. 
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This sequence is conserved in most picornaviruses, which implies that RNA binding has tight 
evolutionary constraints (Matthews et al., 1994; Bergmann et al., 1997; Bergmann &  James, 
1999).     
 
On the opposite face of the molecule to the RNA binding site the active proteolytic site is 
located. In HAV 3Cpro the catalytical triad is composed of cysteine, histidine and aspartic acid 
- however the side chain of aspartic acid does not seem to take part in catalysis. In poliovirus, 
aspartic acid is substituted by glutamic acid, which does take part in catalysis. Although 3Cpro 
is a cysteine protease, this composition of the catalytic triad resembles the enzymes the serine 
proteases of the chymotrypsin family, where a carboxyl group is found in the catalytic triad as 
well. In the cysteine protease papain asparagines is found as third member of the triad. 
Therefore it was discussed whether the reactive nucleophile of the 3Cpro is the thiolate ion of 
the thiolate- imidiazolium ion pair as in papain (Polgar, 1974 and 1989) or the reaction of the 
nondissociated thiol group is catalysed by general base catalysis, a mechanism used in serine 
proteases, where the active site OH group attacks the carbonyl carbon atom of the substrate. It 
was shown that the 3Cpro of poliovirus does not have a catalytically active thiolate- 
imidazolium ion pair (Sárkány et al., 2001). Therefore the imidiazole assistance in hydrolosis 
is very likely general base catalysis as in serine proteases. This is followed by the nucleophilic 
attack on the carbonyl group of the peptide backbone, which frees the amino terminal of the 
backbone. An acyl- enzyme intermediate is formed, then the enzyme is deacylated by a water 
molecule and the carboxy terminal part of the protein is released. The negatively charged 
oxygen of the substrate is stabilized in the oxyanion hole during processing. 
 
1.3.4.  2A protease (2Apro) 
 
The picornaviral 2A protease is a multifunctional enzyme. In rhino- and enteroviruses the 
2Apro performs the first cleavage on the polyprotein by cleaving between its own N-Terminus 
and the C-Terminus of VP1, thereby separating the capsid protein precursor from the non-
structural proteins (Toyoda et al., 1986). Additionally, 2Apro cleaves the two isoforms of 
eIF4G in trans, which leads to the shut-off of host cell translation. The IRES activity is 
maintained or even enhanced after the cleavage of eIF4G by 2Apro (Hambidge & Sarnow, 
1992; Liebig et al., 1993; Ziegler et al.,1995; Borman et al., 1997). Furthermore, 2Apro is 
involved in the cleavage of poly- A- binding- protein (PABP) (Joachims et al., 1999; 
Kerekatte et al., 1999). The interaction of PABP with eIF4G also stimulates the IRES- 
dependent translation (Sachs et al., 1997; Svitkin et al., 2001). This is important in order to 
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achieve sufficient production of viral proteins as the IRES in entero- and rhinoviruses is quite 
weak compared to other picornaviruses (Bormann et al., 1995)). In addition to protein 
processing 2Apro may also play a role in RNA replication (Molla et al., 1993; Yu et al., 1995). 
 
Like 3Cpro the 2A protease was predicted to have a chymotrypsin-like fold by alignment to 
known structures, although they have a cysteine as their active site nucleophile instead of the 
serine of chymotrypsin (Bazan & Fletterick, 1988; Gorbalenya et al., 1989). The crystal 
structure of HRV2 2Apro confirmed these predictions (Petersen et al., 1999) and is shown in 
Figure 7. This revealed more details on the mechanism of both intra- and intermolecular 
cleavage and substrate specificity. The structure and function of the 2Apro will now be 
examined in detail. 
 
As mentioned above the HRV2 2Apro is a cysteine protease with a chymotrypsin-like fold. Its 
overall structure resembles that of Streptomyces griseus proteinase B (SGPB) (Read  et al., 
1983; Petersen et al., 1999) with the 3Cpro of PV1. Similarly, it comprises two subdomains 
built up by -strands that are connected by a so called interdomain loop. However, while 
chymotrypsin-like proteases usually have eight -strands in the N-terminal subdomain, HRV2 
2Apro has only four. Another unusual feature of the HRV2 2Apro is the presence of a tightly 
bound zinc ion coordinated at the beginning of the second subdomain on the opposite face of 
the molecule to the active site by three cysteine and one histidine residue (Cys52, Cys54, 
Cys112 and His114) at the beginning of the second subdomain on the opposite face of the 
molecule to the active site (Sommergruber et al., 1994; Sommergruber et al., 1997; Voss et 
al., 1995). As this zinc ion is not accessible for ligands according to inhibitor studies and 
more than 20Å away from the active site it does not seem to be involved in catalysis, but 
increases the stability of the protein. It seams likely that it maintains stability by 
compensating for the four missing -strands of the N-terminal domain and takes over the role 
of a disulfide bridge found at an equivalent position in extracellular chymotrypsin-like 
proteases. Normally disulfide bridges are not formed inside cells due to the reducing 
environment, so HRV2 2Apro may have evolved the zinc binding site as an alternative to a 
disulfide bridge in order to achieve more stability  (Petersen et al., 1999; Tsukada et al., 1985; 
Glaser et al., 2003). 
 
The catalytical triad of 2A protease is located in the cleft between the N-terminal and the C-
terminal domain and is composed of histidine as acid-base-catalyst, cysteine as a nucleophile 
and aspartic acid. In HRV2 2Apro the position and orientation of the active site residues are 
very similar to that of SGPB, being His18, Asp35 and Cys106 in HRV2 2Apro and His57, 
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Asp102 and Ser195 in SGPB. In HRV2 2Apro the His18 is stabilized by a net of hydrogen 
bonds in which the Asp35 is involved (Matthews et al., 1994).  
 
 
Fig. 7: Crystal structure of HRV2 2Apro 
Ribbon diagramm of the overall structure of HRV2 2 protease that also shows the members of 
the catalytic triad and the coordinated zinc ion. The Figure has been taken from Petersen et 
al., 1999. 
 
The 2A proteinases of rhinoviruses and enteroviruses perform the first cleavage of the 
polyprotein by cleaving in cis between their own N-Terminus and the C-Terminus of VP1. 
This results in the separation of structural proteins from non-structural proteins (Toyoda et al., 
1986). This initial cleavage event occurs co-translationally, which explains the absence of 
full-length viral polyprotein in infected cells.  
Secondly, the 2Apro cleaves the two isoforms of eIF4G in trans. This cleavage separates the 
N-terminal eIF4E binding domain and the C-terminus eIF3 binding domain of eIF4G 
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(Lamphear et al., 1995), thereby precluding the recruitment of capped mRNA to the 
ribosomes (Bormann et al., 1997; Liebig et al., 1993). This leads to a shut-off of the cap-
dependent translation of the host cell (Kräusslich et al., 1987). The translation of viral 
proteins is not disrupted by that as the 5’ UTR of picornaviruses includes an IRES that 
enables cap- independent translation (Jackson et al., 1990; Jang et al., 1990; Belsham & 
Sonenberg, 1996). It was even shown that IRES-dependent initiation of translation is 
stimulated by 2Apro cleavage of eIF4G (Hambidge & Sarnow, 1992; Liebig et al., 1993; 
Ziegler et al., 1995; Bormann et al., 1997).  
 
HRV2 2Apro initially recognises and binds eIF4GI  away from the scissile bond between 
amino acids 600- 674, which are located immediately N-terminal to the amino acids where 
cleavage occurs, but do not include them. Mutagenesis and binding studies located the eIF4G 
binding domains away from the substrate binding cleft, thus representing exosites (Foeger et 
al., 2002, 2003). More work on the processing of eIF4G revealed that eIF4G cleavage is more 
efficient in presence of eIF4E (Haghighat et al., 1996; Ventoso et al., 1998) and in vivo 
studies gave evidence that the two isoforms of eIF4G are not cleaved simultaneously in all 
picornaviruses. During HRV2 infection both isoforms are cleaved after 3 hours, which 
correlates with the host cell shut-off of infected cells (Seipelt et al., 2000). In HRV14, on the 
other hand, eIF4GI is processed after less than 3 hours, while eIF4GII is processed after 5 
hours (Gradi et al., 2003). The host cell shut-off, which is never completed in HRV14, 
correlates with the cleavage of eIF4GII.  
 
As self-processing and eIF4G cleavage are performed by all rhino- and enteroviruses, a 
similar substrate specificity might be anticipated. However, the sequences of HRV2 and 
HRV14 2A proteinases show only 40% amino acid identity (Wang et al., 1998), and 
alignments of the amino acid sequences indicate that HRV14 2Apro is more closely related to 
polioviral or coxsackieviral 2A proteinases. The NMR structure of CVB4 2Apro in terms of 
overall fold, it is similar to the crystal structure of the HRV2 2Apro, but the low level (40%) of 
sequence identity leads to a substantially different surface (Baxter et al., 2006). In the various 
rhino- and enteroviruses, the cleavage site between VP1 and 2Apro shows a large degree of 
variation in its amino acid sequence. The amino acid sequences that are recognised by the 
2Apro in the different cleavage reactions are given in table 5 (cleavage sites are numbered 
according to the nomenclature of Berger & Schechter, 1970).  
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 P5 P4 P3 P2 P1 * P1' P2' P3' P4' 
HRV2 I I T T A * G P S D 
HRV14 D I K S Y * G L G P 
PV1 D L T T Y * G F G H 
CVB4 S L I T T * G P Y G 
eIF4GI T L S T R * G P P R 
eIF4GII P L L N V * G S R R 
Tab.5: Amino acid sequences at the cleavage sites of rhino- and enteroviruses recognised 
by 2Apro: The sequences were taken from the following sources: HRV2 (Skern et al., 1985); 
HRV14 (Stanway et al., 1984); PV1 (Kitamura et al.,1981); CVB4 (Jenkins et al., 1987); 
eIF4GI (Lamphear et al., 1995); eIF4GII (Gradi et al., 1998). The cleavage site is marked by 
the star, the colour code is explained in the text. 
 
As it was mentioned above, the cleavage sites recognised by rhino- and enteroviral 2A 
proteinases are rather heterogeneous. However, the P1’ site of all rhino- and enteroviruses is 
highly conserved. At this position, marked in red in the table above, a glycine is found in all 
serotypes. Mutations in which the P1’ glycine is replaced by another amino acid are 
deleterious in all cases (Glaser & Skern, 2000). 
At the P2’ positions a proline is found in all rhinoviruses except HRV14 and CVB4. Deletion 
of this proline has been shown to eliminate cleavage in HRV2. The crystal structure of HRV2 
2Apro shows that this residue sticks out of the active site (Petersen et al., 1999). In eIF4GII, a 
serine is found at P2’, which is a residue with a short side chain that should be also recognised 
by HRV2 2Apro. This might explain why HRV2 2Apro recognises both eIF4GI and eIF4GII 
equally well (Seipelt et al., 2000). In HRV14 and PV1, the P2’ position is occupied by leucine 
and phenylalanine respectively; both large hydrophobic residues. The hydrophilic serine at the 
eIF4GII P2’ seems to inhibit substrate recognition by 2Apro. It has been shown that a peptide 
that mimics HRV14 recognises HRV14 2Apro 12 times better when the leucine at P2’ is 
substituted with proline (Wang et al., 1998b). However, this is only true in trans cleavage. No 
difference can be seen in the cis cleavage. Additionally, it has to be noted that HRV14 2Apro 
does not recognise the eIF4GI sequence in cis, although it has a proline at P2’. This indicates 
different mechanisms for cis and trans cleavage. In P3’ and P4’, a large variety of amino 
acids can be tolerated. 
At the P1 site, alanine and valine are preferred by most rhinoviruses and enteroviruses. 
However, in HRV14 and polioviruses, a tyrosine is found at P1 (marked in green); in 
coxsackie viruses B1- B4, there is a threonine, both hydrophilic residues. Recent data 
indicates that the tyrosine at P1 plays an important role in substrate recognition in HRV14. It 
has been shown that HRV14 2Apro could not carry out self-processing when the cleavage site 
was replaced by that of eIF4GI. However, replacing of the arginine at P1 of eIF4GI by 
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tyrosine was sufficient to restore the self-processing activity. The substitution of tyrosine by 
arginine in the wild type cleavage site of HRV14 on the other hand eliminated cleavage 
(Sousa et al., 2006). 
At the P2 threonine or asparagine are found in all rhino- and enteroviruses, as well as in 
eIF4GI and eIF4GII, with the exception of HRV14, where serine occupies the P2 position. At 
P3 threonine or lysine are found, only in CVB4 isoleucine is found at P3. The P4 residue is 
aliphatic in all rhino- and enteroviruses. In the sequences used in experiments for this thesis, 
they are always leucine or isoleucine (marked in blue). This indicates that a hydrophobic 
residue at P4 is important in substrate recognition by 2Apro. 
The crystal structure of HRV2 2Apro and the solution structure of CVB4 2Apro (Baxter et al., 
2006) facilitated understanding of the substrate recognition of 2Apro. It has to be remarked 
that given the low level of identity between the different entero- and rhinoviruses, more 
residues involved in substrate recognition may only be recognised when the crystal structures 
of HRV14 2Apro and other picornaviral 2A proteinases become available. 
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2. MATERIALS AND METHODS 
 
2.1. Materials 
2.1.1.  Plasmids 
 
For all in vitro experiments pCITE- A1 (® Novagen) was been used as vector (Fig.8). pCITE- 
A1 includes a CITE- sequence (Cap Independent Transcription Enhancer), that derives from 
encephalomyocarditis virus (EMCV) and facilitates internal initiation of protein synthesis. 
The 3705bp vector codes for a gene that gives resistance to ampicillin. It contains the origin 
of replication of pUC that leads to high yields of plasmid, the promoters T7 and SP6. The 
viral sequences were cloned in the plasmid downstream of the EMCV internal ribosome entry 
site.  
 
Fig.8: pCITE A1 vector 
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For HRV2 and HRV14 the EMCV insert was removed and the DNA-fragments of VP1- 2Apro 
were introduced between the NcoI (2925bp) and BamHI restriction sites. This BamHI 
restriction site was not present in the original Novagen pCITE- 1 (Glaser and Skern, 2000). 
 
2.1.2.  Bacterial strains 
 
For all cloning experiments the bacterial strain E.coli TOP10F’ was used.  
 
2.1.3.  Media 
 
Luria- Bertani (LB) medium: 
• 5 g/l yeast extract (Gibco BRL) 
• 10g/l Pepton (Gibco BRL) 
• 10g/l NaCl (Fluka) 
• pH 7.5 (adjusted with NaOH) 
 
agarose plates:  
• LB medium 
• 1.5 % (w/v) agarose 
 
antibiotics: 
 
ampicillin (1000x stock in H2O; 100mg/ml) 
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2.1.4.  Oligonucleotides 
 
In the table 6 all oligonucleotides that have been used are displayed with their sequence and 
function. 
 
 
Primer Nucleotide Sequence Function 
TIM 
1401 
5' AATTGTGACCAGACCAATTATCACTACAA 
TGGGCCCCAGTGACATGTATGTTCATGTAG 3' 
Creation of the mutant P1M in 
HRV2VP12A (fwd) 
TIM 
1402 
5' 
GTTACCTACATGAACATACATGTCACTGGGGC 
CCATTGTAGTGATAATTGGTCTGGTCAC 3' 
Creation of the mutant P1M in 
HRV2VP12A (rev) 
TIM 
1403 
5' CCGGTAATTAAGAAGAGGAAAGGTGACA 
TTAAATCCATGGGTTTAGGACCGC 3' 
Creation of the mutant P1M in 
HRV14VP12A (fwd) 
TIM 
1404 
5' GGTCCTAAACCCATGGATTTAAT 
GTCACCTTTCCTCTTCTTAATTA 3' 
Creation of the mutant P1M in 
HRV14VP12A (rev) 
TIM 
1435 5' GGACATCAATCCGGAGCCGTGTATGTG 3' 
Introduction of a BspEI restriction 
site into CVB4 VP1 2Apro (fwd)  
TIM 
1436 5' CACATACACGGCTCCGGATTGATGTCC 3' 
Introduction of a BspEI restriction 
site into CVB4 VP1 2Apro (rev)  
TIM 
1437 
5' GATGTTGAGGCGGTTACCGCGGAGCGTGCA 
3' 
Introduction of a BstEII restriction 
site into CVB4 VP1 2Apro (fwd)  
TIM 
1438 
5' TGCACGCTCCGCGGTAACCGCCTCAACATC 
3' 
Introduction of a BstEII restriction 
site into CVB4 VP1 2Apro (rev)  
TIM 
1440 
5' GATCTTAGCACCCGTGGGC 
CCCCAAGGCAAAACAAAGCGGTGTA 3' 
Cassette for the creation of the 
mutant LSTR GPPR in PV1 (fwd) 
TIM 
1441 
5' TACACCGCTTTGTTTTGC 
CTTGGGGGCCCACGGGTGCTAA 3' 
Cassette for the creation of the 
mutant LSTR GPPR in PV1 (rev) 
TIM 
1442 
5' GTTACCGCGGAGCGGACAACCCTTAG 
CACCCGTGGGCCCCCAAGGCATCAAT 3' 
Cassette for the creation of the 
mutant RTTLSTR GPPR in CVB4 
(fwd) 
TIM 
1443 
5' CCGGATTGATGCCTTGGGGGCCCAC 
GGGTGCTAAGGGTTGTCCGCTCCGCG 3' 
Cassette for the creation of the 
mutant RTTLSTR GPPR in CVB4 
(rev) 
TIM 
1479 
5' 
AATTGTGACCAGACCACCTTTGTTGAATGTTGGG 
TCACGAAGAATGTATGTTCATGTAG 3' 
Cassette for the creation of the mutant 
PLLNV GSRR in HRV2 (fwd) 
TIM 
1480 
5' GTTACCTACATGAACATACATTCTTCG 
TGACCCACCATTCAACAAAGGTGGTCTGGTCAC 
3' 
Cassette for the creation of the mutant 
PLLNV GSRR in HRV2 (rev) 
TIM 
1481 
5' CCGGTAATTAAGAAGAGGAAA 
GGTCCTTTGTTGAATGTTGGGTCACGACCGC 3' 
Cassette for the creation of the mutant 
PLLNV GSR in HRV14 (fwd) 
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TIM 
1482 
5' GGTCGTGACCCAACATT 
CAACAAAGGACCTTTCCTCTTCTTAATTA 3' 
Cassette for the creation of the mutant 
PLLNV GSR in HRV14 (rev) 
TIM 
1483 
5' AATTGTGACCAGACCAGACATTAAA 
TCCTATGGTTTAGGACCGATGTATGTTCATGTAG 
3' 
Cassette for the creation of the mutant 
DIKSY GLGP in HRV2 (fwd) 
TIM 
1484 
5' GTTACCTACATGAACATACATCGGTCCT 
AAACCATAGGATTTAATGTCTGGTCTGGTCAC 3' 
Cassette for the creation of the mutant 
DIKSY GLGP in HRV2 (rev) 
TIM1485 5' CCGGTAATTAAGAAGAGGAAGGTATTATCAC TACAGCTGGCCCCAGTCCGC 3' 
Cassette for the creation of the mutant 
IITTA GPSP in HRV14 (fwd) 
TIM1486 5' GGACTGGGGCCAGCTGTAGTGATA ATACCTTTCCTCTTCTTAATTA 3' 
Cassette for the creation of the mutant 
IITTA GPSP in HRV14 (rev) 
TIM 
1524 
5' CCGGTAATTAAGAAGAGGAAAGGTCCTTTGTT 
GAATTATGGGTCACGACCGC 3' 
Cassette for the creation of the mutant 
PLLNY GSR in HRV14 (fwd) 
TIM 
1525 
5' GTTCGTGACCCATAATTCAACAAAGGACCTTT 
CCTCTTCTTAATTA 3' 
Cassette for the creation of the mutant 
PLLNY GSR in HRV14 (rev) 
TIM 
1534 
5' CCGGTAATTAAGAAGAGGAAAGGTC 
CTTTGTTGAATTATGGCTCGAGACCGC 3' 
Cassette for the creation of the mutant 
PLLNY GSR in HRV14 with AvaI 
restriction site (fwd) 
TIM 
1535 
5' GGTCTCGAGCCATAATTCAACAAAGGA 
CCTTTCCTCTTCTTAATTA 3' 
Cassette for the creation of the mutant 
PLLNY GSR in HRV14 with AvaI 
restriction site (rev) 
TIM 
1536 
5' CCGGTAATTAAGAAGAGGAAAGGTATTAT 
CACTACAGCTGGCCCGAGTCCGC 3' 
Cassette for the creation of the mutant 
IITTA GPSP in HRV14 with AvaI 
restriction site (fwd) 
TIM 
1537 
5' GGACTCGGGCCAGCTGTAGTGATAATACCTTT 
CCTCTTCTTAATTA 3' 
Cassette for the creation of the mutant 
IITTA GPSP in HRV14 with AvaI 
restriction site (rev) 
TIM 
1538 
5' AATTGTGACCAGACCACCTTTGTTGAATGTT 
GGCTCGAGAAGAATGTATGTTCATGTAG 3' 
Cassette for the creation of the mutant 
PLLNV GSRR in HRV2 with AvaI 
restriction site (fwd) 
TIM 
1539 
5' GTTACCTACATGAACATACATTCTTCTCGAG 
CCAACATTCAACAAAGGTGGTCTGGTCAC 3' 
Cassette for the creation of the mutant 
PLLNV GSRR in HRV2 with AvaI 
restriction site (rev) 
TIM 
1540 
5' 
AATTGTGACCAGACCAATTATCACTACAATGGG 
CCCGAGTGACATGTATGTTCATGTAG 3' 
Creation of the mutant A M  with AvaI 
restriction site (fwd) 
TIM 
1541 
5' GTTACCTACATGAACATACATGTCACTC 
GGGCCCATTGTAGTGATAATTGGTCTGGTCAC 3' 
Creation of the mutant A M  with AvaI 
restriction site (rev) 
TIM 
1542 
5' AATTGTGACCAGACCAGACATTAAATCA 
TATGGTTTAGGACCGATGTATGTTCATGTAG 3' 
Cassette for the creation of the mutant 
DIKSY GLGP in HRV2 with NdeI 
restriction site (fwd) 
TIM 
1543 
5' GTTACCTACATGAACATACATCGGTCCTAAA 
CCATATGATTTAATGTCTGGTCTGGTCAC 3' 
Cassette for the creation of the mutant 
DIKSY GLGP in HRV2 with NdeI 
restriction site (rev) 
TIM 
1312 5' ATACATCAAGGTTTAGTG 3' Sequencing of HRV14 VP1 2A
pro
 (fwd) 
TIM 
1332 5’ CATGCCATGGCCTGTTCCTCTGCGATACA 3' Sequencing of HRV14 VP1 2A
pro
 (rev) 
TIM 
1333 5' CATGCCATGGGCCCCAGTGACATGTATGT 3' Sequencing of HRV2 VP1 2A
pro
 (fwd) 
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TIM 
1323 5' TTTGGGATAGTACGGACTTTCCTGTAT 3' Sequencing of HRV2 VP1 2A
pro
 (rev) 
TIM 550 5' GGACGTGGTTTTCCTTTG 3' Sequencing of pCITE- 1a IRES (fwd) 
TIM 554 5' ATTTAGGTGACACTATAG 3' Sequencing of pCITE- 1a SP6 (rev) 
TIM 
1196 5' GGATGTCCATACCGTTCATG 3' Sequencing of CVB4 VP1 2A
pro
 (fwd) 
TIM 
1098 5' ACTCACTAGAAGATCTCTATTATAATC 3' Sequencing of CVB4 VP1 2A
pro
 (rev) 
TIM 
1350 5' GACCAAGGTCACCTCCAA 3' Sequencing of PV1 VP1 2A
pro
 (fwd) 
TIM 
1351 5' TCCATGGCTTCTTCTTCG 3' Sequencing of PV1 VP1 2A
pro
 (rev) 
TIM 592 5' ACAGACCATGGTTGAGAATTATATAGATG 3' Sequencing of HRV2 VP1 2Apro (fwd) 
TIM 
1505 5' TGTAATTGGGAAGTATCTATTTTTATG 3' Sequencing of HRV2 VP1 2A
pro
 (rev) 
TIM 
1506 5' GTTAGAGTAGTCAATGATCACAACCCG 3' Sequencing of PV1 VP1 2A
pro
 (fwd) 
TIM 
1507 5' TTCGTAGGCATACAAGTCTCTAAT 3' Sequencing of PV1 VP1 2A
pro
 (rev) 
Tab.6. Nucleotide sequences of all used primers and their function 
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2.2.  Methods 
 
2.2.1.  Preparation of competent cells 
 
Competent Top10F’ cells were prepared using the CaCl2 method. To this end, 200µl of 
bacteria were inoculated in 3ml LB at 37°C over night. Following this, the culture was grown 
in 200ml of LB to an OD600 of 0.6. The bacteria were harvested in sterile tubes at 5000rpm for 
5min. at 4°C. The medium was discarded and the cells were resuspended in 25ml of ice-cold 
0,1M CaCl2 and left in ice for 25min. Then, they were centrifuged at 5000rpm for 5 min. at 
4°C, the medium was discarded again and the cells were resuspended in 10ml of 0.1M ice-
cold CaCl2 and left at 4°C over night. Finally, 2ml of sterile 80% glycerol were added and 
aliquots of 200µl were frozen in liquid nitrogen. The competent cells were stored at -80°C. 
 
2.2.2. Transformation of competent cells 
 
A 200µl aliquot of competent cells was thawed on ice for 10 min, then the DNA was added 
and left on ice for 15min. 10µl DNA from a ligation mix or 1µl DNA from a midi prep were 
used. Following this, the cells were heat shocked at 42°C for 45 seconds and transferred to ice 
immediately. 400ml of prewarmed LB were added and the mix was incubated at 37°C for 30 
minutes. Following this, the samples were plated on agarose plates containing ampicillin. The 
plates were incubated at 37°C over night. 
 
2.2.3. DNA preparation 
 
Mini preps 
 
Mini preps are used for the quick isolation of a larger amount of plasmid DNA of transformed 
bacteria from over night cultures that were grown in 3ml of LBAMP. This method allows 
checking for positive clones after transformation. Positive clones can be identified by 
digestion with restriction enzymes or DNA sequencing. 
 
3 ml of bacteria culture were grown over night in LBAMP (100µg/ml) at 37°C. 1,5ml of the 
culture were transferred to eppendorf tubes and spinned down at 13000rpm for 30 sec. The 
supernatant was discarded and the previous steps were repeated with another 1.5ml of 
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bacterial culture. Following this, the pellet was resuspended in 100µl of buffer S1, then 
treated with 200µl of lysis buffer S2, mixed gently and incubated at room temperature for 3 
min. 150µl of neutralizing buffer S3 were added and the sample was mixed gently but 
thoroughly again. The sample was spinned down at 13000rpm for 5 min. at 4°C and the 
supernatant was transferred to a clean eppendorf tube. 1ml of ice-cold ethanol was added and 
spinning at 4°C was repeated. The pellet was resuspended in 200µl of water and 200µl of 5M 
LiCl were added and centrifuged again. The supernatant was transferred to a new tube, 1ml of 
ice-cold EtOH was added and the sample was spinned down at 4°C again. Following this, the 
pellet was air dried and resuspended in 50µl of water. 
 
All used buffers were taken from the Nucleobond AX kit for Plasmid DNA preparation.  
 
Midi preps 
 
Midi preps are used to isolate larger amounts of very pure plasmid DNA that can be used for 
further cloning experiments or in vitro transcription. 
 
100 ml of bacteria culture were grown over night at 37°C in LBAMP (100µg/ml) and then the 
plasmid DNA was isolated using the Nucleobond AX kit for Plasmid DNA preparation. 
 
The bacteria were harvested at 5000rpm for 5min. at 4°C, the supernatant was discarded and 
the pellet was resuspended in 4ml of buffer S1. 4ml of buffer S2 were added and the sample 
was incubated for 3 min. Following this, 4 ml of buffer S3 were added, the sample was mixed 
and centrifuged at 10000rpm for 25min. at 4°C. The lysate was loaded onto a column that had 
been equilibrated with buffer N2. The column was washed with 10ml of washing buffer N3 
and then the sample was eluted with 5ml of buffer N5. 3,5ml of isopropanol were added and 
the sample was centrifuged at 11000rpm for 30min. at 4°C. The supernatant was discarded, 
2ml of 70% were added to the pellet and then it was centrifuged at 11000 rpm for 10min. The 
pellet was air dried and the DNA was reconstituted in 200µl of H2O. 
 
2.2.4. DNA purification 
 
DNA or RNA that has been contaminated or treated with enzymes has to be purified. During 
purification, proteins and salts can be removed. Two methods of DNA purification were used. 
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Phenol- chloroform- extraction 
 
2µl of EDTA were added to the sample to stop enzyme reactions. Then 1 volume of phenol 
was added, the sample was vortexed and centrifuged at 13000rpm for 2min. The supernatant 
was transferred to a new tube, 1 volume of Chloroform was added, the sample was vortexed 
and centrifuged for 2 min. again. The extraction was followed by the Na- acetate 
precipitation. For that purpose 2 volumes of absolute EtOH and 10% of Na- acetate were 
added and the sample was incubated at -80°C for 20min. The sample was centrifuged at 
13000rpm for 15min. at 4°C, the pellet was air dried and resuspended in 50µl water or TE 
buffer (10mM Tris, 1mM EDTA, adjusted to pH 7.5 using HCl). 
 
DNA clean-up using Wizard SV gel and PCR clean-up system 
 
1 volume of binding solution is added to the sample, the mixture is transferred to a column, 
incubated for 1 min. and centrifuged at 13000rpm for 1 min. The flow-through is discarded, 
700µl of washing solution are applied onto the column and after 1min of centrifugation the 
flow-through is discarded again. 500µl of wash solution are added, and a centrifugation of 
5min follows. The flow-through is discarded, the column is dried by 1min. centrifugation with 
the lid of the centrifuge opened. Finally the column is transferred into a new tube and the 
sample is eluted with 50µl H2O. 
 
2.2.5. Gel extraction of DNA fragments 
 
Agarose gels (1%) are used to check the size and purity of DNA fragments resulting from 
analytical digests with restriction enzymes. In preparative digestions one of several fragments 
can be isolated from an agarose gel. 
 
Gel extraction was performed using QIAquick- kit: 
 
First, the DNA fragment was excised from the agarose gel and transferred to an eppendorf 
tube. 3 volumes of QG buffer were added and the mix was incubated at 50°C for 10min. in 
order to dissolve the agarose. After dissolution of the agarose 1 volume of isopropanol was 
added and the mix was loaded onto a column. The column was centrifuged at 13000rpm for 1 
min., the flow-through was discarded and 500µl of QG buffer were added. After 1min. 
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centrifugation 750µl PE buffer were added, the mix was centrifuged again and the column 
was transferred to a new tube. The DNA was eluted with 50µl of H2O. 
 
2.2.6. Enzyme reactions 
 
Restriction digests 
 
For all restriction digests enzymes and 10x buffers of New England Biolabs (NEB) were 
used. 
 
The following set-ups were used: 
 
Analytical digestion:   5µl DNA (Mini prep) 
2µl NEB buffer (10x) 
0.5µl enzyme [20 000 U/ml] 
12.5µl H2O 
 
20µl total volume 
 
Preparative digestion: 30µl DNA (Midi prep) 
10µl NEB buffer (10x) 
1.5 µl enzyme [20 000U/ml] 
58.5 µl H2O 
 
100µl total volume 
 
Dephosphorylation 
 
Dephosphorylation of the template is performed prior to ligation in order to prevent religation 
of the template. This is especially important in blunt end ligation. This was done with CIP 
(Calf intestinal alkaline phosphatase). 
0.5ml of 2M Tris- HCl (pH 8.0) were added to 48.5µl of the restricted and purified DNA. The 
mix was incubated with 1µl of CIP (10U/µl, ® NEB) at 37°C for 45min., then CIP was 
inactivated at 65°C for 45min. 
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Kinasing oligos 
 
The oligos that are used for a ligation are treated with PNK T4 (Polynucleotide kinase 
T4).This is done by PCR (Polymerase chain reaction) of a mix containing: 
 
2µl ATP (100mM) 
2µl PNK buffer (10x, Fermentas) 
1µl oligo 1 (1µg/µl, VBC Biotech) 
1µl oligo 2 (1µg/µl, VBC Biotech) 
1µl PNK T4 (10000 U/ml, Fermentas) 
13µl H2O 
 
The following PCR settings were used: 
 
37°C   30min. 
90°C   30sec. 
37°C    5min. 
  4°C     
1 cycle 
 
Ligation 
 
The enzyme ligase is capable of connecting two pieces of DNA that have been restricted with 
the same enzymes. Therefore it is crucial in cloning an insert into a vector. 
For all experiments T4 DNA ligase (10U/µl, ® NEB) was used. For a 20µl ligation mix of 
vector and insert 0.5µl T4 DNA ligase, 2µl T4 ligase buffer (10x) and 2µl of 100mM ATP 
were added. The ligation was incubated over night at room temperature, and then the sample 
was stored at 4°C until it was used for transformation. 
 
2.2.7. Cassette cloning 
 
Cassette cloning is a method that allows the rapid insertion of mutations into a vector. Two 
oligos of opposite sense that carry the mutation aimed on are connected and kinased (see 
2.2.6). The oligo cassette is then ligated with the readily cut vector. 
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2.2.8. Site directed mutagenesis 
 
For investigation of protein structure and function, the substitution of one or more amino 
acids is an important feature. While substitutions of several nucleotides are performed with 
cassette cloning, the substitution of up to three nucleotides can be performed with site 
directed mutagenesis. 
This method uses a cycle PCR that amplifies the DNA sample. The oligos are designed in a 
way so the amino acid that shall be exchanged is located in the middle of them. As said before 
a mismatch of up to 3 nucleotides can be tolerated. Therefore, the oligos should contain 
approximately 10 nucleotides on each side of the mismatch. A negative control without the 
oligos has to be performed as well. 
Following the PCR, the sample was digested with DpnI at 37°C for at least 5 hours. DpnI is a 
restriction enzyme that cleaves a sequence of 4 nucleotides, but only recognized this sequence 
when it is methylated. This means that it only digests the template strain, whereas the newly 
synthesized strain remains unaffected. After this digestion, the PCR product is transformed 
into Top10F’ competent bacteria. 
 
The following set up has been used: 
1µl template DNA 
0.5µl primer 1 (fw) (1g/l) 
0.5µl primer 2 (rv) (1g/l) 
2µl dNTPs 
5µl PFU buffer (10x, Promega) 
0.5µl PFU polymerase (Promega) 
40.5µl H2O 
 
PCR- settings: 
95°C     2min. 
95°C   30sec. 
50°C     1min. 
68°C   12min. 
  4°C     
35 cycles 
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Where no PCR product was found, the annealing temperature was lowered to 50°C. The 
duration of the annealing was calculated from the length of the plasmid, i.e. 2min. per kb + 2 
additional minutes. For CVB4 with a length of about 5kb that results in 12min. annealing. 
 
Site directed mutagenesis and cassette cloning are compared in Fig.9. 
 
Fig. 9: Comparison of cassette cloning and site directed mutagenesis 
(a) shows the steps of cassette cloning: First, the vector is cut with two restriction enzymes in 
order to remove the part of the DNA in which the mutation will be inserted. Two oligos of 
opposite sense that carry the mutation aimed on are connected and kinased. The DNA 
fragment carrying the mutation and the vector are then joined by ligase. (b) shows the 
introdution of a mutation by site directed mutagenesis. In this method a cycle PCR is used to 
amplify the DNA sample. Two oligos are designed in a way so the amino acid that shall be 
exchanged is located in the middle of them. Low annealing temperatures allow that the 
mutation is introduced into the newly synthesized strands. Following this, the PCR mix is 
digested with DpnI in order to remove the template DNA. Figure 9 has been extracted from 
[6]. 
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2.2.9. In vitro transcription 
 
For the production of RNA, the template must be first linearized. pCITE-1a VP1 2Apro of 
HRV2 and HRV14 were linearized with the enzyme BamHI, whereas PstI was used for the 
linearization of CVB4 and SacI for PV1. For all linearizations, about 5µg template DNA were 
used. 20 to 40µl template were mixed with 10µl NEB buffer (10x) and 1µl enzyme and 
replenished with H2O to 100µl. The mix was incubated for at least 3 hours at 37°C. When 
linearization was incomplete after 3 hours, longer incubation times were used. After 
linearization the product was purified. 
 
Transcription mix (100µl total): 
 
50 µl purified template DNA 
20µl transcription buffer (5x) 
  5µl DTT (100mM) 
10µl NTP mix (2,5mM) 
  3µl RNAsin 
  1µl T7 polymerase 
11µl H2O (RNAse free) 
 
The mix was incubated for 90 min. at 37°C, then 0.6µl DNAseI (30 units) and 1µl RNAsin 
(40 units) were added and incubation at 37°C was continued for 20 more minutes. Following 
this, the RNA was purified using phenol/chloroform- extraction. Instead of sodium acetate 
precipitation an ammonia acetate precipitation was carried out. After extraction, 2.5 volumes 
of 96% EtOH and 1/3 volume of NH4Ac (8M) were added and the mix was incubated at -
80°C for 15min. The precipitated RNA was resuspended in 25µl RNAse free water. The 
amount and quality of the RNA were checked on a 1% agarose, 0.1% SDS gel. 
 
2.2.10. In vitro translation 
 
For all in vitro translation experiments rabbit reticulocyte lysates (RRL) were used. In order 
to check whether the mutants are capable of self processing and to find the exact time point at 
which self processing takes place, time course experiments were run. For short range time 
courses the time points 0, 5, 10, 20, 30 and 60 minutes were examined, for long range 
experiments the time points were set at 30, 60, 90, 120 and 180 minutes. The total volume of 
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the translation mix was 10µl for one time point. For each time point observed 1 volume of the 
translation mix was added. The appropriate RNA amount was checked previously by 
translating several dilutions of RNA. 
 
Translation mix (10µl): 
 
7   µl RRL 
0.2µl Amino acid mix – methionine 
0.2µl RNAsin 
0.4µl 35S labelled- methionine 
1.2µl H2O 
1   µl RNA dilution 
 
The translation mix was incubated for 2 min at 30°C without RNA, then the RNA was added. 
At each time point one volume of translation mix (10µl) was stopped by adding the mix to 
41µl of ice cold stop mix, consisting of 1µl methionine/cysteine mix (20mM), 25µl Laemmli 
sample buffer (2x) and 15µl H2O. The 5x Laemmli sample buffer consists of 50%glycerol, 
25% ß- mercapto- ethanol, 15% SDS, 315mM Tris HCl (pH 6.8) and 25% (w/w) 
bromophenol blue. 
 
The translation product was separated by SDS- PAGE. 
 
2.2.11. Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
SDS- PAGE is a widely used technique for separating proteins according to their size, which 
is their mass in kD. For this thesis the polyacrylamide gel electrophoresis system described by 
Dasso & Jackson (1989) was used for analysis of translation products. The samples are boiled 
for 5 minutes for denaturation prior to loading the gel. The ß- mercapto- ethanol contained in 
the Laemmli sample buffer reduces disulfide bridges, so full denaturization is guaranteed. The 
SDS adds a strong negative charge to the protein so the length of the protein corresponds to 
the protein mass. Without SDS, different proteins with similar molecular weights would 
migrate differently due to differences in folding, which would make some proteins fit better 
through the gel matrix than others. With SDS added the proteins are negatively charged. This 
allows separating the proteins only according to their mass. The grade of interlacing of the 
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acrylamide is also designated by the size of the polyprotein and its cleavage product. In this 
case 17.5% acrylamide gels were used. 
 
Resolving gel: 
 
1020 µl acrylamide 
  209 µl bisacrylamide 
1050 µl LGS buffer (4x) 
  750 µl H2O 
    30 µl APS (10%) 
      3 µl TEMED 
 
A stacking gel was placed on top of the resolving gel. This stacking gel has larger pores and a 
different pH, so the proteins are able to migrate fast and without being separated through the 
stacking gel. When the reach the interface between stacking gel and resolving gel their 
migration is decelerated considerably and the new migration speed is now corresponding to 
the size of the proteins resulting in separation. 
 
Stacking gel: (stock) 
 
  6.5 ml acrylamide 
12.5 ml UGS buffer (4x) 
31    ml H2O 
For each gel 2ml of the stock are used and 12µl APS (10%) and 4µl TEMED are added. 
LGS buffer consists of 1,5M Tris and 0,4% SDS, pH 6,8, UGS buffer has the same 
composition, but the pH adjusted to 8,8. 
 
The readily prepared gel is then loaded with the samples. The 10x running buffer contains 
250mM Tris, 2 M glycerol and 1% SDS. 
 
The detection of the radioactively labelled translation product was done by fluorography 
(Laskey, 1980). Therefore the stacking gel was washed 2 times 15minutes in enhancing buffer 
after running. The Enhancer consists of 32g sodiumsalicylate, 90ml methanol and 110ml H2O 
and washes away the radioactive background while enhancing the right signals. After 
washing, the gels were dried on 3mm Whatman paper for 1hour at 80°C. Then a Kodak 
Biomax MR film was placed on the gel and the film was exposed for approximately 24 hours 
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at -80°C. As radioactive marker 14C- CFA 626 (® Amersham Pharmacia Biotech) was used, 
which gives bands at 220, 97.4, 66, 46, 30, 14 and 3kDa. 5µl of the marker and 10µl of the 
samples were loaded on the gel. 
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3. AIMS 
 
All members of the picornavirus family are small, non-enveloped icosahedral viruses with a 
single stranded RNA genome of positive sense. Their genomic information is translated into a 
single polyprotein of about 200 kDa that is cleaved to mature proteins by the viral proteases 
2A and 3C. 2A Protease (2Apro) exerts the first cleavage in rhino- and enteroviruses and 
separates structural from non-structural proteins (Toyoda et al., 1986). In order to do so, it 
cuts between its own N-Terminus and the C-Terminus of capsid protein VP1. Following this, 
2Apro cleaves between the two isoforms of eukaryotic initiation factor 4G (eIF4G), a 
translation factor of the host cell that plays an important role in cap- dependent translation. 
This second cleavage leads to a shut-off of host- cell translation, whereas viral translation is 
not affected as it is cap- independent. 
 
Several picornaviruses are known to be the causative agents of human and animal diseases 
which makes them an important issue for research. As the 2Apro is highly conserved among 
rhino- and enteroviruses it is a potential target for antiviral drugs. In order to develop effective 
inhibitors an understanding of the substrate specificity of the picornaviral proteases is highly 
important. 
 
Proteins of four members of the Picornavirus family were examined in this thesis: human 
rhinovirus (HRV) 2 and 14 are two of more than 100 serotypes of human rhinoviruses, which 
are the main causative agent of common cold (Couch, 1990), a disease that is reported to be 
an important economical factor as it causes absences from work (Bramley et al., 2002; 
Fendrick et al., 2003). The 2Apro of the two rhinoviruses were chosen as they differ 
significantly in their amino acid sequence and the receptor they use (Skern et al., 1985; 
Colonno, 1986). While HRV2 is an A- group rhinovirus of the minor group that uses LDL 
receptors, HRV14 belongs to the B- group and is a major group rhinovirus as it uses ICAM as 
receptor. The HRV2 and HRV14 2Apro share only 40% amino acid sequence identity and 
show remarkable differences in the two 2Apro cleavage reactions. This is especially true for 
the cleavage of eIF4G. Additionally one member of coxsackie viruses, Coxsackie virus B4 
(CVB4) and one of poliovirus, PV1, were examined. Coxsackie B viruses are reported to be 
related with internal diseases (Kayser et al., 1998) and are a cause of myocarditis, which is 
connected with congestive cardiomypathy, a severe disorder of the heart (Liu et al., 1993). 
Furthermore, CVB4 is a possible cause of Diabetes mellitus type I. CVB4 is an enterovirus 
with about 40% sequence identity with HRV2. Structural identity is also given for large parts. 
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Poliovirus 1 (PV1), the causative agent of poliomyelitis, is also an enterovirus however, it 
shows some similarity to HRV14. 
 
Although the sequences of the different picornaviral 2A proteases are known and structural 
predictions were made due to sequence alignments with known structures, a crystal structure 
is only available for HRV2 2Apro (Petersen et al., 1999). Recently, the solution structure of 
CVB4 2Apro was published (Baxter et al., 2006). The structures revealed some details about 
the mechanism and substrate specificities of the picornaviral 2A proteases, but still many 
questions about their function remain unanswered. In order to gain understanding of the 
activity of picornaviral self-processing and cleavage of eIF4G the cleavage specificities of 
HRV2, HRV14, PV1 and CVB4 2Apro were examined and compared in this thesis. 
 
The comparison of the activities of the 2Apros of these viruses was performed in vitro in rabbit 
reticulocyte lysate (RRL). The self-processing, that is the cleavage of the polyprotein, 
between 2Apro and VP1 was assayed. 
 
First, the amino acids at the P1 position in HRV2 and HRV14 were changed into a 
methionine in order to find out how this might affect the self-processing. This substitution 
was especially interesting as the same mutation enhanced the cleavage in bacteria. An 
increased cleavage efficiency has also been shown for synthetic peptides substituted with 
methionine at the P1 (Sommergruber et al., 1992). 
 
Following this, the cleavage site of HRV2 and HRV14 was replaced by a cassette with the 
sequence of eIF4GII. This was done to find out whether the cleavage site of eIF4GII could 
still be recognised in a changed environment. The data then could be compared to the results 
of the same experiments with insertion of eIF4GI. (Sousa et al., 2006; Schmid, 2002). 
 
The influences of a substitution of the cleavage site by the sequence of eIF4GI on the self-
processing was then analysed for PV1 and CVB4. This was especially interesting as it could 
be compared with the results for HRV2 and HRV14. For these proteinases it had been shown 
that HRV2 2Apro was able recognise and cleave eIF4GI when it was introduced between VP1 
and 2A on the polyprotein, while HRV14 2Apro was not (Sousa et al., 2006). As the 2Apro of 
HRV2 resembles that of CVB4 in some aspects and PV1 shows some similarity to HRV14, it 
was of great interest to examine how they were influenced by the introduction of eIF4GI into 
the polyprotein.  
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Additionally, the cleavage sites of HRV2 and HRV14 were interchanged in order to examine 
the effect on the self-processing. Given the low amino acid sequence identity of only 40% 
between the 2A proteases of HRV2 and HRV14 and the difference in the cleavage reactions it 
was an intriguing question whether the 2Apro proteases would be able to recognise the 
significantly different cleavage site of the respective other 2Apro when inserted between VP1 
and 2Apro. 
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4. RESULTS 
 
4.1.  Introduction of methionine at P1 position in HRV2 VP1 2Apro 
and HRV14 VP1 2Apro: 
 
2Apro executes the first cleavage reaction in picornaviruses, which is the cleavage between its 
own N-Terminus and the C-Terminus of VP1. It has been shown previously that substitution 
of the amino acid tyrosine at P1 position by methionine results in accelerated cleavage of the 
polyprotein. This was demonstrated in bacteria and with synthetic peptides. Now, it was to be 
tested whether this enhanced self-processing was also observed in a more sensitive system, 
that of the rabbit reticulocyte lysate. 
 
To examine the efficacy of self processing from the polyprotein, the mutants HRV2 VP1 
2Apro P1M and HRV14 VP1 2Apro P1M were constructed. Then, the plasmid DNA was 
prepared, linearised and used for in vitro transcription. A concentration of approximately 
10ng/µl RNA was used. A time course of translation was carried out using 0min, 5min, 
10min, 20min, 30min and 60min as time points. The wild type constructs HRV2 VP1 2Apro 
wt and HRV14 VP1 2Apro wt were used as positive controls, water as a negative control. After 
translation the proteins were boiled 2 min. at 95°C and 10µl aliquots loaded on a 17.5% 
polyacrylamide gel and analysed by fluorography. 
 
In wild type HRV2 VP1 2Apro self-processing the first protein bands are visible after 10min. 
After 20min, 50% of the polyprotein is cleaved and after 60min cleavage is complete 
(Fig.10). The uncleaved species has a size of approx. 49kDa; the band can be seen a little 
above the 46kDa marker. VP1 has a size of about 33.5kDa, the band is placed significantly 
above the 30kDa marker, which suggests a retarded migration. 2Apro has a size of 15,5 kDa, 
the band can be seen above the 14kDa marker. The 2Apro band is quite weak as it is difficult 
to detect by autoradiography as 2Apro contains only two methionines, whereas VP1 contains 
eight. 
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In the mutant HRV2 VP1 2Apro A  M, the self-processing cleaves at wild type rates. The 
first protein bands are visible after 10min, 50% are cleaved after 20min and after 60min 
cleavage is completed (Fig.11). Whether the cleavage works better compared to the wild type, 
as observed in bacteria and with peptides, could not be observed in this translation 
experiment. Specific data on the kinetics of the cleavage would be necessary to investigate 
this.  
 
Fig.10:Self- processing of HRV2-VP1-2Apro wild type during in 
vitro translation. RRL were incubated with the mRNA as 
described in “materials and methods”. Aliquots were taken at the 
set time points and translation stopped by addition of a 2mM mix of 
unlabelled methionine and cysteine and Laemmli buffer followed 
by placing the samples on ice. The aliquots were analysed by 17,5% 
SDS- PAGE to investigate the cleavage of VP1-2Apro. The 
fluorogramm was exposed at -80°C for 20 hours. The position of 
uncleaved VP1-2Apro and the fragments of VP1 and 2Apro after 
cleavage are marked. Radioactively labelled CFA- 626 (Amersham 
™) was used as marker. 
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Figure 12 shows that the self processing performance in wild type HRV14 VP1 2Apro is very 
similar to that in HRV2. Cleavage is only slightly delayed in comparison to HRV2, starts after 
20min, is 50% complete after 30min and almost complete after 60min. 2Apro is easier to 
detect in HRV14 as it contains three methionines, VP1 has six. 
In the mutant HRV14 VP1 2Apro Y  M the cleavage is slightly retarded compared to the 
wild type. Although the protease started to cleave itself out of the polyprotein after 20min like 
in the wt, less than 50% were cleaved after 30min and cleavage was not totally completed 
after 60min. This is shown in Fig.13. 
 
 
Fig.11: Self-processing during in vitro translation of HRV2-
VP1- 2Apro with the alanine at P1 changed into methionine. The 
mRNA was analysed as described in Fig.10. Uncleaved VP1-2Apro 
and the cleavage product VP1are marked. After 20 min. 50% of 
VP1- 2Apro are cleaved, after 60 minutes cleavage is completed. 
This efficiency corresponds to the cleavage of the wild type. 
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Fig.12: Self- processing of HRV14-VP1-2Apro wild type during 
in vitro translation. The mRNA HRV14-VP1-2Apro was analysed 
as described in Fig.10. Uncleaved VP1-2Apro and the cleavage 
products VP1 and 2Apro are marked. 
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Fig.13: Self- processing during in vitro translation of HRV14- 
VP1- 2Apro with the tyrosine at P1 changed into methionine. 
The self- processing of the mRNA HRV14-P1M was analysed as 
described in Fig.10. Uncleaved VP1-2Apro and the cleavage 
product VP1 are marked. Cleavage started after 20min, was less 
than 50% completed after 30 min and almost completed after 
60min. 
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4.2. Insertion of the 2Apro cleavage site of HRV14 into HRV2, and the 
2Apro cleavage site of HRV2 into HRV14: 
 
HRV2 and HRV14 are two serotypes of human rhinovirus that differ significantly. HRV2 is a 
minor- group member, which means that it uses LDL- receptors, whereas HRV14 belongs to 
the major group viruses and use ICAM receptors. HRV2 and HRV14 show only 51% identity 
in their amino acid sequence, their 2A proteases are only 40% identical (Wang et al., 1998). 
To find out what happens when the cleavage sites of HRV2 and HRV14 between VP1 and 
2Apro are removed from their original protein context, new mutants were created using 
cassette cloning. 
 
Eight amino acids of the cleavage site of HRV2 VP1 2Apro, IITTA * GPS; were replaced by 
the corresponding region of HRV14 VP1 2Apro, DIKSY * GLGP and vice versa. After 
cloning of the mutants, the linearized templates were transcribed in vitro. Following this, the 
mRNAs were translated in vitro and translation was monitored by autoradiography to 
investigate whether the 2Apro was still able to recognise the cleavage site and cut itself out of 
the polyprotein in spite of the mutated amino acid sequence. 
 
Fig.14 shows that if the sequence of HRV14 is transferred to HRV2, no cleavage can be 
observed during 180 minutes of in vitro translation 
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Fig.14: Self- processing of HRV2- VP1- 2Apro with the cleavage 
site of HRV14-VP1-2Apro inserted during in vitro translation. 
The cleavage of the polyprotein by 2Apro was analysed as described 
in Fig.10. Uncleaved VP1-2Apro is marked. The polyprotein was 
not cleaved within 180 min. 
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Different results occurred when the cleavage site of HRV2 was transferred to HRV14, as can 
be seen in Figure 15. During the first 60 minutes again no cleavage was observed, but after 60 
minutes translation started and after 180 minutes approximately 50% of the polyprotein were 
cleaved. 
Fig.15: Self- processing of HRV14- VP1- 2Apro with the cleavage 
site of HRV2- VP1- 2Apro inserted during in vitro translation. 
The cleavage of the polyprotein by 2Apro was analysed as described 
in Fig.10. Uncleaved VP1-2Apro and the cleavage product VP1 are 
marked. No cleavage could be observed before the 60 minutes time 
point. After 180 min. almost 50% of the polyprotein were cleaved. 
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4.3. Insertion of the cleavage site of eIF4GII into HRV2 and HRV14: 
 
The 2A protease of picornaviruses executes two cleavage reactions that are crucial in the viral 
life cycle. First, it cleaves itself out of the polyprotein during self-processing, as described in 
chapter 1.3. Secondly, it cleaves the two isoforms of eukaryotic initiation factor 4G (eIF4G) 
resulting in the shut-off of host cell translation. While self-processing proceeds very similar in 
HRV2 and HRV14, there are remarkable differences in vivo in the cleavage of the two 
isoforms of eIF4G. eIF4GI is cleaved significantly slower by HRV14 than by HRV2. eIF4GII 
is cleaved by HRV2 simultaneously with eIF4GI, whereas it is cleaved remarkably later by 
HRV14 during in vitro translation (Gradi et al.,2003; Foeger et al., 2003). It has been shown 
that in vitro cleavage of eIF4GI by HRV2 2Apro is extremely efficient having a molar ratio 
similar to that observed during infection in vivo (Glaser & Skern, 2000). Due to the 
degradation of the RRL after 6 hours it is not clear whether eIF4GII is cleaved at all by 
HRV14 in vitro.  
 
In order to gain information on the eIF4GI cleavage site, the sequence of the cleavage site was 
removed from its original protein surroundings and introduced into the polyprotein between 
VP1 and 2Apro.  Therefore, the sequences IITTA * GPSD and DIKSY * GLGP that are 
cleaved by HRV2 and HRV14 2Apro on the respective polyprotein were replaced by the 
TLSTR * GPPR sequence that is cleaved on eIF4GI by HRV2 2Apro. It was shown that the 
HRV2 2Apro still was able to recognise the cleavage site and cut itself out of the polyprotein, 
while HRV14 was not able to do so due to the presence of arginine at P1 (Sousa et al., 2006). 
Now we wished to examine, whether the same was true for the second isoform, eIF4GII. 
 
The sequence of the cleavage site of VP1 2Apro was therefore substituted by the cleavage site 
of eIF4GII, being PLLNV * GSRR. This was done by cassette cloning as explained in 
material and methods (2.2.7). Nine amino acids of the VP1 2Apro cleavage site on the 
polyprotein of HRV2 and eight of HRV14 were replaced by the amino acids of the cleavage 
site of eIF4GII. During in vitro translation the 2Apro of HRV2 and HRV14 now had to be able 
to recognise the eIF4GII cleavage site in cis in order to free themselves from of the 
polyprotein. After cloning the mutants they were again transcribed into RNA and then 
translated in vitro. The results of in vitro translation are shown in Fig.14. 
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As can be seen in Figure 16a, no cleavage could be observed after 60min. Subsequently, a 
longer range time course was run, adding time points after 90min, 120min and 180min. 
Figure 16b shows that after 180min, cleavage had still not started, as only VP1-2Apro was 
visible. The HRV2 2Apro was therefore unable to recognise the eIF4GII cleavage site in a 
different protein context. 
 
Fig.16: Self-processing of HRV2- VP1-2Apro with insertion of 
the eIF4GII cleavage site during in vitro translation. Analysis 
was performed as described in Fig.10. Uncleaved VP1-2Apro is 
marked. No self-processing could be examined after 60min (A). 
After 180min still only the uncleaved product is visible, no 
cleavage took place (B). 
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Figure 17 shows the results for HRV14. It can be seen that again no cleavage was executed 
after 60min. As for HRV2, a longer time course was run. No cleavage of eIF4GII could be 
examined, giving evidence that the 2Apro of HRV14 is also not able to recognise the eIF4GII 
cleavage site in cis. 
 
It could be shown that HRV14 was able to recognise eIF4GI in cis, when the arginine at the 
P1 position of eIF4GI was substituted by the tyrosine of the wild type cleavage site of HRV14 
VP1 2Apro (Sousa et al.,2006). Thus we examined whether the same was true for the cleavage 
of eIF4GII. The valine at the P1 position of eIF4GII was substituted by tyrosine, as in the 
HRV14 wild type. The remainder of the eight amino acids of the eIF4GII cleavage site 
remained unchanged, creating the sequence PLLNY * GSRR. After transcription, the mutant 
RNA was in vitro translated in order to find out whether the substitution was sufficient to 
regain self-processing of the 2Apro. 
 
Fig.17: Self-processing of HRV14-VP1-2Apro with the cleavage 
site of eIF4GII inserted during in vitro translation. The cleavage 
of the polyprotein was analysed as described in Fig.10. Uncleaved 
VP1-2Apro is marked. No cleavage occured during 300 min of in 
vitro translation. 
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Figure 18 shows that replacing the valine at P1 by tyrosine was indeed sufficient to regain the 
function of HRV14 2Apro to a certain degree. Cis cleavage of the eIF4GII started after 60min 
and was almost completed after 180min. 
 
 
Fig.18: Self- processing of HRV14-VP1-2Apro with the cassette 
PLLNY*GSR inserted during in vitro translation. The mRNA 
was analysed as described in Fig.10. Uncleaved VP1-2Apro and the 
cleavage product VP1 are marked. No cleavage could be examined 
for 60 min. At this time cleavage of the polyprotein started and was 
almost complete after 180 min. 
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4.4.  Insertion of the cleavage site of eIF4GI into PV1 and CVB4: 
 
As mentioned earlier, previous experiments examined how HRV2 and HRV14 2Apro function 
when the cleavage site of eIF4GI is introduced instead of the original cleavage site. HRV2 
was still able to recognise the cleavage site and cut eIF4GI in cis, whereas HRV14 could not. 
As the 2Apro of all picornaviruses performs the cleavage of the two isoforms of eIF4G in 
trans, it was of interest whether other picornaviruses would be able to recognise the cleavage 
site in cis, as can be done by HRV2 2Apro. Two picornaviruses, one serotype of poliovirus, 
PV1, and one of coxsackie virus, CVB4, were therefore examined. 
 
The eight amino acids LTTY * GFGH of PV1 VP1 2Apro and 11 amino acids RASLITT * 
GPYG of CVB4 VP1 2Apro were replaced by the cleavage sequence of eIF4GI by cassette 
cloning, being LSTR * GPPR for PV1 and RTTLSTR * GPPR for CVB4 2Apro. For CVB4 
two restriction sites, BstEII and BspEI, had to be created to enable the introduction of the 
cassette. This was done by site directed mutagenesis. Again, the clones were in vitro 
transcribed into RNA and then translated in vitro in RRLs. 
 
First, the differences in the in vitro translation of PV1 VP1 2Apro wild type and CVB4 VP1 
2Apro wild type were examined. In Fig.19, it can be seen that the cleavage of PV1 VP1 2Apro 
started after 20 minutes and was completed after 180 minutes. In case of CVB4 VP1 2Apro 
50% of the polyprotein were cleaved after 20 minutes, after 60 minutes cleavage was almost 
completed (Fig.20). 
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Fig.20: Self- processing of CVB4- VP1- 2Apro during in vitro 
translation. 
The mRNA CVB4-VP1-2Apro was analysed as described in Fig.10. 
Uncleaved VP1-2Apro and the cleavage product VP1 are marked. 
After 20 min. 50% of VP1- 2Apro are cleaved, after 60 min cleavage 
is almost completed.  
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Fig.19: Self-processing of PV1- VP1- 2Apro from the polyprotein 
during in vitro translation. The mRNA was analysed as described 
in Fig.10. Uncleaved VP1-2Apro and the cleavage products VP1 
and 2Apro are marked. Cleavage of the polyprotein started after 20 
minutes translation but was not completed after 180 min. 
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Figure 21 demonstrates the translation of PV1 with the cleavage site of eIF4GI introduced. 
The 2Apro was able to recognise the cleavage site of eIF4GI in cis. Cleavage started slightly 
delayed compared to the wild type after 30 minutes. However, after 180 minutes more than 
50% were cleaved. 
 
 
 
 
In figure 22 it can be seen that the 2Apro of CVB4 is also able to recognise eIF4GI in cis. It 
cleaves the mutant carrying eIF4GI with a similar efficiency to the wild type, with cleavage 
starting after 20 minutes and being almost complete after 60 minutes translation. 
 
Fig.21: Self-processing of PV1-VP1-2Apro with the cleavage site 
of eIF4GI inserted during in vitro translation. The cleavage of 
the polyprotein by 2Apro was analysed as described in Fig.10. 
Uncleaved VP1-2Apro and the cleavage products VP1 and 2Apro are 
marked. Cleavage started after 30 min. and more than 50% were 
cleaved after 180 min. 
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Fig.22: Self-processing during in vitro translation of CVB4- 
VP1- 2Apro with the cleavage site of eIF4GI inserted. Analysis of 
the mRNA was performed as described in Fig.10. Uncleaved VP1-
2Apro and the cleavage product VP1 are marked. Cleavage started 
after 20 min. and was almost completed after 60 min. 
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5. DISCUSSION 
 
5.1. Introduction of methionine at P1 position in HRV2 VP1 2Apro 
and HRV14 VP1 2Apro 
 
As mentioned in the introduction, rhino- and enteroviruses are able to tolerate a wide variety 
of amino acids at the P1 position. Replacement of the alanine at the P1 of HRV2 by 
methionine has been shown to result in more efficient cleavage by 2Apro. However, this data 
is only available for bacteria and synthetic peptide substrates, where the relative cleavage 
efficiency was shown to be fivefold higher than that of the wild type (Sommergruber et al., 
1992). This makes methionine an interesting target for the development of an inhibitor. It has 
been shown that zVAM.fmk, an inhibitor with methionine at P1, was more efficient in 
inhibiting intermolecular cleavage by HRV2 2Apro than zVAD.fmk (Deszcz et al., 2006). In 
this thesis, the cleavage of HRV2 and HRV14 with the mutation P1M was examined in a 
more sensitive system, RRLs. 
 
A time course in vitro translation was used to assay the exact time points at which cleavage 
takes place. In wild type HRV2 VP1 2Apro, the first bands are visible after 10min, after 20min 
50% are cleaved and after 60min self-processing is completed. For the mutation HRV2 VP1 
2Apro P1M, a similar result could be observed. The first bands were observed after 20min 
50% were cleaved and after 60min cleavage was completed. This indicates that self-
processing in the mutant carrying the methionine instead of the P1 alanine works equally well 
as in the wild type. To find out whether cleavage of the mutant is more efficient than that of 
the wild type, further studies on the kinetics of the cleavage have to be done. 
 
The results for HRV14 are quite similar to that of HRV2. The start of the self-processing of 
wild type HRV14 VP1 2Apro is slightly delayed in comparison to that of HRV2 VP1 2Apro. 
Cleavage starts after 20min, after 30min 50% are cleaved and after 60 min the self-processing 
is completed. Here, the mutant with the methionine at the P1 showed a slightly retarded 
cleavage compared to the wild type. Self-processing of HRV14 VP1 2Apro P1M started after 
20min, but was less than 50% completed after 30min and not completely finished after 60min. 
As in the case of HRV2, further studies would need to be done to obtain detailed information 
on the kinetics of the cleavage reaction. 
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These results show that the substitution of the alanine and the tyrosine at the P1 of HRV2 and 
HRV14, respectively, with methionine does not lead to a loss of function in self-processing 
even if the translation is tested in a sensitive system. This corresponds with the data in the 
literature for the self-processing in bacteria and with synthetic peptides and the successful use 
of the zVAM.fmk inhibitor (Sommergruber et al., 1992; Deszcz et al., 2006). However, it has 
to be said that no increase in the cleavage efficiency could be monitored, as this was the case 
for bacteria and synthetic peptide.  
 
5.2. Insertion of the cleavage site of eIF4GII into HRV2 and HRV14 
 
In addition to self-processing (Toyoda et al., 1986), the 2Apro of rhino- and enteroviruses also 
cleaves between the two isoforms of eIF4G after it has cleaved itself out of the polyprotein 
(Lloyd et al., 1988; Gradi et al., 1998). This cleavage is a crucial step in the viral life cycle as 
it leads to a shut-off of host cell translation (Kräusslich et al., 1987; Lloyd et al., 1987; Jewell 
et al., 1990). The exact mechanism is described in chapter 1.2. This second cleavage of 2Apro 
is performed in trans in contrast to the self-processing which is performed in cis. An 
interesting question is whether the sequences for this cleavage can also be recognised by 2Apro 
in cis when they are inserted into the cleavage site between VP1 and 2Apro on the polyprotein. 
This means finding out whether the amino acid sequence at the cleavage sites of the two 
isoforms of eIF4G are also recognised by 2Apro when they are removed from their native 
protein surroundings and put in the polyprotein context. For HRV 2 and HRV14, this has 
already been examined for eIF4GI (Sousa et al., 2006; Schmid, 2002). It has been shown that 
HRV2 2Apro is able to recognise the cleavage site of eIF4GI in cis and self-processing was 
performed with kinetics that were similar to that of the wild type. On the other hand, the 2Apro 
of HRV14 was not able to recognise eIF4GI in cis and no self-processing was observed. 
Further experiments demonstrated that HRV14 VP1 2Apro cannot accept the arginine at the P1 
position, found at P1 in eIF4GI. Substitution of the arginine at the P1 in eIF4GI by the 
tyrosine of wild type HRV14 VP1 2Apro was sufficient to restore the self-processing activity 
but not to wild type levels.  
 
In this thesis, a similar experimental set up has been used to test whether the 2Apro is able to 
recognise the other isoform of eIF4G, eIF4GII, in cis when it is removed from its original 
protein context. Mutants were created, in which the amino acids IITTA * GPSD of the 
cleavage site of HRV2 VP1 2Apro and DIKSY * GLGP of HRV14 VP1 2Apro, respectively, 
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were replaced by the amino acid sequence PLLNV * GSRR of the cleavage site for 2Apro on 
eIF4GII.  
 
For the HRV2 mutant, no self-processing activity could be monitored during 180min of in 
vitro translation. This means that the 2Apro was not able to recognise the cleavage site of 
eIF4GII in cis. For HRV14, very similar results were observed. Again, no self-processing 
activity was monitored, showing that HRV14 2Apro was not able to recognise the eIF4GII 
sequence in cis. As has been shown for eIF4GI that the arginine at P1 could not be tolerated 
by the HRV 14 2Apro, it was assumed that the valine at the P1 position of eIF4GII would also 
not be tolerated. Therefore, the valine at P1 of eIF4GII was substituted by the tyrosine of the 
wild type. The experiments showed that the replacement of the valine at P1 by tyrosine was 
sufficient to regain self-processing activity. The cis cleavage of eIF4GII started after 60min 
and was completed after 180min. However, the delay of the start of self-processing in 
comparison to the wild type indicates that other residues are involved in the recognition of the 
P1 residue. As HRV2 and HRV14 2Apro share only 40% amino acid sequence identity it will 
only be possible to identify such residues when the crystal structure of HRV14 2Apro becomes 
available. Furthermore, it would be interesting to examine whether the self-processing activity 
of HRV2 2Apro as well is regained if the valine at the P1 of eIF4GII is substituted by the 
alanine of the wild type. 
 
5.3. Insertion of the cleavage site of eIF4GI into PV1 and CVB4 
 
As discussed in 5.2, it was examined whether the 2Apro of HRV2 and HRV14 are able to 
recognise the cleavage sites of eIF4G in cis when they are removed from their native protein 
surroundings. This showed that the specificity of HRV2 2Apro and HRV14 2Apro differ 
significantly at P1.  
 
Therefore, it is of interest to compare the substrate binding of HRV14 2Apro to that of 
poliovirus 1 and coxsackievirus B4, which are both related to HRV14. It has to be remarked 
that CVB4 and PV1 2Apro share about 58% sequence identity, which means that they are even 
more closely related than HRV2 and HRV14 2Apro (Jenkins et al., 1987). 
 
During infection HRV14 and PV1 both cleave eIF4GI more rapidly than eIF4GII, which 
indicates that the respective 2Apro poorly recognises the eIF4GII cleavage site in comparison 
to that of eIF4GI (Gradi et al., 1998; Svitkin et al., 1999). HRV2 2Apro on the other hand 
cleaves eIF4GI and eIF4GII equally well during infection (Seipelt et al., 2000). 
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It was examined in this thesis whether the 2Apro of CVB4 and PV1 were able to recognise the 
cleavage site of eIF4GI in cis or whether self-processing activity would be lost as this is the 
case for HRV14 2Apro. 
 
It was reported in the results that CVB4 2Apro was still able to recognise the cleavage site of 
eIF4GI in cis and self-processing was maintained to almost wild type level. When the same 
experiment was repeated for PV1, the mutant that carried the cleavage site of eIF4GI self-
processing was also maintained, although slightly delayed compared to the wild type. The 
experiments showed that PV1 and CVB4 were able to recognise the cleavage site of eIF4GI 
in cis.  
 
It has been shown for HRV2 and HRV14 2Apro that the amino acid at P1 position plays a 
major role in cis processing of eIF4GI (Sousa et al., 2006). As discussed in 5.2, HRV14 2Apro 
could not accept the arginine at P1 instead of the wild type tyrosine. PV1 on the other hand, 
which carries a tyrosine at the P1 position as well, was able to tolerate arginine at P1. Self-
processing was maintained in the mutant although delayed compared to the wild type.  
Therefore, it is of interest to examine which residues are involved in the recognition of the P1 
amino acid. The crystal structure of HRV2 2Apro revealed that the side chain of residue C101 
protrudes into the S1 pocket on the enzyme recognising the P1 (Petersen et al., 1999). In the 
pocket the negatively charged side chain of E102 probably helps accepting the positive charge 
of the P1 arginine of eIF4GI. For the HRV14 2Apro resididue A104, which is the equivalent to 
HRV2 2Apro C101, a similar role in substrate recognition has been revealed (Sousa et al., 
2006). This indicates that amino acid positions equivalent to residue 101 in HRV2 2Apro are 
also involved in the substrate recognition of other picornaviral 2A proteases. 
 
In poliovirus 1 2Apro a tyrosine is found at P1 and an alanine at residue 104, which is 
equivalent to HRV2 2Apro residue 101. As the same residues as in PV1 are found in HRV14 
2Apro it is surprising that PV1 2Apro was able to cleave eIF4GI in cis, although delayed to the 
wild type, while HRV14 2Apro was not. This indicates that other residues are involved in the 
recognition of the P1 residue as well. It has to be remarked that it is still not determined 
whether the cleavage site of HRV14 on eIF4GI is identical to that used by HRV2, PV1 and 
CVB4 (Lamphear et al., 1993; Zamora et al., 2002) which might be another explanation for 
the differences between HRV14 and PV1 cis cleavage of eIF4GI. Therefore, it will be 
important to identify this cleavage site for HRV14. 
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5.4. Insertion of the cleavage site of HRV14 into HRV2, the one of 
HRV2 into HRV14 
 
HRV2 and HRV14 are two out of one hundred serotypes of human rhinovirus (Rueckert et 
al., 1996). They differ to a large extent. Their amino acid sequence shows overall only 51% 
identity, the sequences of their 2A proteases are only 40% identical (Wang et al., 1998). The 
2Apro of HRV14 is more closely related to that of CVB4 and PV1. Within the group of 
rhinoviruses, they are divided into different groups. HRV2 is classified as a group A 
rhinovirus and belongs to the minor group, which means that it uses LDL- receptors. HRV14 
on the other hand is classified as a group B rhinovirus of the major group, which means it 
uses ICAM- receptors (Savolainen et al., 2002b; Duechler et al., 1993). Due to the differences 
in their sequences it is difficult to gain information for HRV14 from the crystal structure of 
HRV2 (Petersen et al., 1999). Although the catalytical triad is identical for both, the sequence 
of HRV14 differs from that of HRV2 in several important regions. Most important, the 
cleavage for self-processing is IITTA * GPSD for HRV2 2Apro, that of HRV14 2Apro is 
DIKSY * GFGH: At residue 101, which plays an important role in substrate recognition, as 
discussed in 5.3, a cysteine is found in HRV2. At the equivalent position in HRV14 an 
alanine is found. Still, their overall structures, the viral life cycles and the proteolytical 
activity of 2Apro are similar. While different cleavage sites are recognised by HRV2 2Apro and 
HRV14 2Apro during self-processing, both 2A proteases are able to recognise and cleave 
eIF4GI and eIF4GII.  
 
Therefore it was of interest whether the 2Apro of HRV2 would be able to recognise the 
cleavage site of HRV14 and vice versa when they are introduced between VP1 and 2A. We 
showed here that the 2Apro of HRV2 is not able to recognise the cleavage site of HRV14 in 
cis. It was shown that HRV2 2Apro can accept a tyrosine, as present in HRV14 at P1 position 
without significant impairment of self-processing. Substitution of the P’ region of HRV2 by 
that of HRV14 on the other hand proved to be deleterious (Skern et al., 1990). Therefore, the 
residues at the P’ region are likely to be responsible for the loss of self-processing activity that 
was monitored after insertion of the HRV14 cleavage site. Although the P’ region is highly 
conserved in rhinoviral 2A proteases, that of HRV14 differs significantly from the other 
2Apro. At P1’ in all serotypes a glycine is found, mutations replacing that amino acid are 
deleterious in all cases (Glaser & Skern, 2000). While this is also true for HRV14, at P2’ in 
HRV14 a leucine is found, where all other rhinoviral 2Apro have a proline. It has been shown 
that substitution of the proline at P2’ eliminated cleavage (Skern et al., 1990). The crystal 
structure of HRV2 2Apro (Petersen et al., 1999) revealed that the proline sticks out of the 
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active site. The leucine found in HRV14 at this position is a large hydrophobic residue which 
probably can not be recognised by HRV2 2Apro. Furthermore, HRV14 also differs 
significantly from HRV2 2Apro at the P2 position. In HRV14, serine is present, while in all 
other rhino- and enteroviruses threonine or asparagine are found. They might also interfere 
with substrate recognition by HRV2. Creation of further deletion mutants could be used to 
determine whether other residues are involved as well. 
 
In contrast to HRV2, HRV14 2Apro did recognise the cleavage site of HRV2 in cis and was 
still able to cleave itself from the polyprotein. It has to be remarked that self-processing of the 
mutant was significantly slower than that of wild type HRV14. Previous work on the HRV14 
substrate specificity was limited to synthetic peptides. It was shown that HRV14 2Apro poorly 
cleaves a peptide corresponding to its wild type cleavage site in vitro. Cleavage was improved 
when the peptide resembled more the HRV2 2Apro cleavage site (Wang et al., 1998b). This 
data shed no light on the P1 specificity as the P1 position of the peptides examined was 
always tyrosine as in the wild type. Recently it was revealed that HRV14 can not accept an 
arginine at P1, as its found in eIF4GI (Sousa et al., 2006). It would be interesting to replace 
the tyrosine at P1 of HRV14 2Apro by the alanine found in HRV2 2Apro to find out whether 
this residue is responsible for the retarded self-processing of HRV14 after then insertion of 
the HRV2 cleavage site. 
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6. SUMMARY AND ZUSAMMENFASSUNG 
 
6.1.  Summary 
 
This diploma thesis deals with the picornaviral 2A proteinases of two serotypes of human 
rhinovirus, HRV2 and HRV14, as well as one serotype of poliovirus, PV1, and 
coxsackievirus, CVB4. The cleavage specificities of these proteases were examined by 
monitoring the self-processing activity. Different mutants were created by cassette cloning 
and the effect of the mutations on the self-processing was investigated. 
First, it was examined whether a substitution of the amino acid at the P1 position of HRV2 
and HRV14 2Apro by a methionine would  enhance in vitro translation in rabbit reticulocyte 
lysate (RRL), as it does in bacteria and on synthetic peptide substrates. We show here that in 
vitro translation in RRLs of a mutation of HRV2 2Apro with methionine at P1 works as well as 
that of the wild type, but does not enhance it. For HRV14 2Apro P1M cleavage was even 
slightly retarded compared to the wild type. 
The next step was to find out whether the 2Apro of HRV2 and HRV14 was able to cleave the 
eIF4GII cleavage site in cis when embedded in the polyprotein. The same experiment has 
already been done with the sequence of the cleavage site of eIF4GI, showing that HRV2 2Apro 
can recognise eIF4GI in cis while HRV14 2Apro is not able to do so. After constructing the 
mutants and in vitro translating the corresponding RNA, we discovered that both respective 
2Apros of HRV2 and HRV14 were not able to exert self-processing. This means that neither of 
the two proteases was able to cleave the eIF4GII cleavage site in cis.  
Following this, we showed that substitution of the valine at P1 of the eIF4GII mutant by the 
tyrosine of the wild type was sufficient to regain self-processing activity in HRV14. Self-
processing was not regained to wild type level, indicating that other residues are involved in 
the substrate recognition. 
A similar experiment was then arranged for PV1 and CVB4 in which it was tested whether 
their 2A proteinases were able to cleave the eIF4GI cleavage site in cis. Our experiments 
showed that both PV1 and CVB4 2Apro were able to cleave eIF4GI in cis and self-processing 
activity was sustained, although slightly delayed in comparison to the wild type. This is 
surprising as in PV1 a tyrosine is found at P1 position and an alanine is found on the residue 
equivalent to 101 in HRV2 2Apro. As these residues are equivalent to HRV14, which is not 
able to cleave eIF4GI in cis, this indicates that either other residues are involved or the 
HRV14 might not have the same eIF4GI cleavage site as HRV2, PV1 and CVB4. CVB4 
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2Apro additionally has a more polar surface than HRV2, so a different cleavage mechanism 
might be used. 
Finally, it was observed whether the 2Apro of HRV2 would be able to cleave the HRV14 VP1- 
2A cleavage site when embedded into the HRV2 polyprotein and vice versa. We discovered 
that HRV2 was not able to cleave HRV14 when embedded into its own polyprotein. Indeed, 
self-processing activity was completely lost. This is probably due to the P’ region of HRV14 
2Apro, as it differs significantly from that found in all other rhinoviruses. Different results 
were observed for HRV14. The 2Apro of HRV14 still was able to cleave itself out of the 
mutated polyprotein. It has to be remarked that self-processing started significantly delayed in 
comparison to the wild type. 
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6.2. Zusammenfassung 
 
Die vorliegende Diplomarbeit beschäftigt sich mit den picornaviralen 2A Proteasen zweier 
Serotypen des humanen Rhinovirus, HRV2 und HRV14, sowie mit jeweils einem Serotyp der 
Polioviren, PV1, und der Coxsackieviren, CVB4. Die Spezifität des Schnittverhaltens dieser 
Proteasen wird anhand der Selbstprozessierungsaktivität untersucht. Verschiedene Mutanten 
wurden mittels Kassettenklonierung hergestellt und die Auswirkungen der Mutationen auf die 
Selbstprozessierung wurden untersucht. 
Zunächst wurde untersucht, ob eine Substitution der Aminosäure an der P1 Position von 
HRV2 oder HRV14 durch ein Methionin in der Lage ist, die in vitro Translation in RRL zu 
beschleunigen, wie das bereits in Bakterien und für synthetische Peptide gezeigt wurde. In 
dieser Arbeit stellten wir fest, dass die in vitro Translation der HRV2 2Apro Mutante mit dem 
Methionin an der P1 Position in RRL so effektiv abläuft wie für den Wildtyp, jedoch nicht 
beschleunigt ist. Für HRV14 2Apro P1M zeigte sich sogar ein leicht verzögertes 
Schnittverhalten. 
Der nächste Schritt war es, herauszufinden ob die 2Apro von HRV2 und HRV14 in der Lage 
ist, die Schnittsequenz von eIF4GII in cis zu erkennen, wenn diese in das Polyprotein 
eingebettet ist. Ein ähnliches Experiment wurde bereits mit der Schnittsequenz von eIF4GI 
durchgeführt, die ebenfalls in das Polyprotein eingebaut worden war. Diese Experimente 
zeigten, dass die 2Apro von HRV2 in der Lage war, die Schnittsequenz in cis zu erkennen, 
während die 2Apro von HRV14 dies nicht konnte. Nach Konstruktion der Mutanten und in 
vitro Translation der entsprechenden RNA fanden wir heraus, dass die jeweiligen 2A 
Proteasen von HRV2 und HRV14 nicht in der Lage waren, die Schnittsequenz von eIF4GII in 
cis zu erkennen. 
Anschließend zeigten wir, dass die Substitution des Valins an der P1 Position der eIF4GII 
Mutante durch das Tyrosin des Wildtyps ausreichend war um die Selbstprozessierung von 
HRV14 VP12A wieder zu aktivieren. Es muss jedoch erwähnt werden, dass der Grad der 
Selbstprozessierung des Wildtyps nicht wiederhergestellt werden konnte, was nahe legt, dass  
zusätzlich andere Reste an der Substraterkennung beteiligt sind. 
Ein ähnliches Experiment wurde dann für PV1 und CVB4 durchgeführt. In diesem wurde 
untersucht, ob deren 2A Proteasen die Schnittsequenz von EIF4GI in cis erkennen können. 
Unsere Experimente zeigten, dass sowohl die PV1 als auch die CVB4 2A Protease eIF4GI in 
cis erkennen konnten und die Selbstprozessierung aufrechterhalten werden konnte, auch wenn 
sie, im Vergleich mit dem Wildtyp, leicht verzögert stattfand. Das sit überraschend, da an P1 
in PV1 2Apro ein Tyrosin vorliegt und die Position äquivalent zu 101 in HRV2 mit Alanin 
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besetzt ist. Das entspricht der Besetzung dieser Reste in HRV14 2Apro, das eIF4GI in cis nicht 
erkennen kann. Daraus lässt sich schließen, dass entweder zusätzlich andere Reste an der 
Substraterkennung beteiligt sind oder HRV14 eIF4GI vielleicht an einer anderen Stelle 
schneidet als PV1, HRV2 und CVB4. CVB4 2Apro besitzt darüber hinaus eine viel polarere 
Oberfläche als HRV2, was möglicherweise auf die Benutzung eines anderen Mechanismus 
hinweist. 
Abschließend wurde untersucht, ob die 2A Protease von HRV2 in der Lage ist, die 
Schnittsequenz von HRV14 zu erkennen, wenn diese in das HRV2 Polyprotein eingebettet ist. 
Das gleiche Experiment wurde umgekehrt auch für HRV14 durchgeführt. Unsere 
Experimente zeigten, dass HRV2 die Schnittsequenz von HRV14 auf dem eigenen 
Polyprotein nicht erkennen und schneiden konnte, es war keinerlei 
Selbstprozessierungsaktivität zu beobachten. Das liegt vermutlich an der P’ Region von 
HRV14 2Apro, die sich deutlich von der aller anderen Rhinoviren unterscheidet. Für HRV14 
zeigten sich jedoch andere Ergebnisse: Die 2A Protease war in der Lage, die Schnittsequenz 
von HRV2 eingebettet in das eigene Polyprotein zu erkennen und sich aus dem mutierten 
Polyprotein herauszuschneiden. Es muss jedoch erwähnt werden, dass auch hier nicht die 
Geschwindigkeit der Selbstprozessierung des Wildtyps erreicht werden konnte. 
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